US6429221B1
(en)
*
|
1994-12-30 |
2002-08-06 |
Celgene Corporation |
Substituted imides
|
US6858589B2
(en)
|
1996-01-25 |
2005-02-22 |
Pharmacy And Therapeutic Advisory Consultancy Pty Ltd |
Methods of and compositions for potentiating the action of agents active on cell wall sites of the susceptible bacteria
|
US5900258A
(en)
*
|
1996-02-01 |
1999-05-04 |
Zeolitics Inc. |
Anti-bacterial compositions
|
DE69739181D1
(de)
*
|
1996-08-12 |
2009-02-05 |
Celgene Corp |
Neue immunotherapeutische Mittel und deren Verwendung in der Reduzierung von Cytokinenspiegel
|
DE19706978A1
(de)
*
|
1997-02-21 |
1998-08-27 |
Ulrich Dr Posanski |
Kombinationspräparat für oral applizierbare Antibiotika
|
JP2003522103A
(ja)
|
1998-06-15 |
2003-07-22 |
セプラコア インコーポレーテッド |
無呼吸、過食症およびその他の障害を治療するための光学的に純粋な(−)−ノルシスアプリドの使用
|
TR200003708T2
(tr)
*
|
1998-06-15 |
2001-06-21 |
Sepracor Inc. |
Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (+)-norsisapridin kullanımı.
|
US6974838B2
(en)
|
1998-08-24 |
2005-12-13 |
Sepracor Inc. |
Methods of treating or preventing pain using sibutramine metabolites
|
JP2000128774A
(ja)
|
1998-10-26 |
2000-05-09 |
Tanabe Seiyaku Co Ltd |
薬物を含有する球形微粒子の製法
|
US6342533B1
(en)
*
|
1998-12-01 |
2002-01-29 |
Sepracor, Inc. |
Derivatives of (−)-venlafaxine and methods of preparing and using the same
|
US6342496B1
(en)
|
1999-03-01 |
2002-01-29 |
Sepracor Inc. |
Bupropion metabolites and methods of use
|
US6548082B1
(en)
|
1999-03-01 |
2003-04-15 |
Sepracor Inc. |
Methods for treating apnea and apnea disorders using optically pure R(+) ondansetron
|
US6337328B1
(en)
|
1999-03-01 |
2002-01-08 |
Sepracor, Inc. |
Bupropion metabolites and methods of use
|
US6362202B1
(en)
|
1999-03-02 |
2002-03-26 |
Sepracor Inc. |
Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
|
US6353005B1
(en)
|
1999-03-02 |
2002-03-05 |
Sepracor, Inc. |
Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
|
US6410052B1
(en)
|
1999-03-30 |
2002-06-25 |
Purdue Research Foundation |
Tea catechins in sustained release formulations as cancer specific proliferation inhibitors
|
US6428818B1
(en)
|
1999-03-30 |
2002-08-06 |
Purdue Research Foundation |
Tea catechin formulations and processes for making same
|
DE60039132D1
(de)
|
1999-04-06 |
2008-07-17 |
Sepracor Inc |
O-Desmethylvenlafaxin-Succinat
|
CN1190185C
(zh)
|
1999-04-06 |
2005-02-23 |
埃迪克埃迪法姆药品实验室 |
可饮用布洛芬药物悬浮液
|
US6951873B1
(en)
|
1999-04-27 |
2005-10-04 |
Pfizer Inc. |
Methods for treating age-related behavioral disorders in companion animals
|
ATE318135T1
(de)
|
1999-09-03 |
2006-03-15 |
Apbi Holdings Llc |
Verwendung von dapoxetin, a selektiver serotonin- aufnahme inhibitor mit schnellem wirkungseintritt,zur behandlung von sexueller dysfunction
|
WO2001036604A2
(en)
|
1999-11-18 |
2001-05-25 |
Corvas International, Inc. |
Nucleic acids encoding endotheliases, endotheliases and uses thereof
|
US7182953B2
(en)
*
|
1999-12-15 |
2007-02-27 |
Celgene Corporation |
Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
|
CN1419446A
(zh)
*
|
2000-01-27 |
2003-05-21 |
田边制药株式会社 |
缓释制剂及其制法
|
US7700341B2
(en)
|
2000-02-03 |
2010-04-20 |
Dendreon Corporation |
Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
|
WO2001074362A1
(en)
*
|
2000-03-31 |
2001-10-11 |
Celgene Corporation |
Inhibition of cyclooxygenase-2 activity
|
US7259152B2
(en)
|
2000-06-07 |
2007-08-21 |
Alfa Wasserman, Inc. |
Methods and compositions using sulodexide for the treatment of diabetic nephropathy
|
US20070208087A1
(en)
|
2001-11-02 |
2007-09-06 |
Sanders Virginia J |
Compounds, compositions and methods for the treatment of inflammatory diseases
|
JP4242651B2
(ja)
*
|
2000-11-30 |
2009-03-25 |
ザ チルドレンズ メディカル センター コーポレイション |
4−アミノ−サリドマイドエナンチオマーの合成法
|
US20030167524A1
(en)
*
|
2000-12-19 |
2003-09-04 |
Rooijen Gijs Van |
Methods for the production of multimeric protein complexes, and related compositions
|
CN101671260A
(zh)
*
|
2001-02-12 |
2010-03-17 |
惠氏公司 |
制备o-去甲基-文拉法辛的方法
|
FR2821745B1
(fr)
*
|
2001-03-09 |
2004-07-02 |
Ethypharm Lab Prod Ethiques |
Granules et granules enrobes au gout masque
|
FR2821747B1
(fr)
*
|
2001-03-09 |
2004-07-02 |
Ethypharm Lab Prod Ethiques |
Suspension de telithromycine a gout masque
|
AU2002305052A1
(en)
|
2001-03-13 |
2002-09-24 |
Corvas International, Inc. |
Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
|
JP2004535166A
(ja)
|
2001-03-22 |
2004-11-25 |
デンドレオン・サンディエゴ・リミテッド・ライアビリティ・カンパニー |
セリンプロテアーゼcvsp14をコードする核酸分子、コードされるポリペプチドおよびそれに基づく方法
|
NZ527971A
(en)
|
2001-03-27 |
2006-03-31 |
Dendreon Corp |
Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
|
WO2002092841A2
(en)
|
2001-05-14 |
2002-11-21 |
Dendreon San Diego Llc |
Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
|
AU2002346065A1
(en)
*
|
2001-07-05 |
2003-01-21 |
Marantech Holding, Llc |
Methods of using electron active compounds for managing conditions afflicting mammals
|
US20030087963A1
(en)
|
2001-09-13 |
2003-05-08 |
Senanayake Chris H. |
Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
|
AU2002357004A1
(en)
*
|
2001-11-20 |
2003-06-10 |
Dendreon San Diego Llc |
Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
|
WO2003049673A2
(en)
|
2001-12-05 |
2003-06-19 |
Baylor College Of Medicine |
Methods and compositions for control of bone formation via modulation of sympathetic tone
|
US20040009953A1
(en)
*
|
2002-01-10 |
2004-01-15 |
Comper Wayne D. |
Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
|
US20030181416A1
(en)
*
|
2002-01-10 |
2003-09-25 |
Comper Wayne D. |
Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
|
JP4583760B2
(ja)
|
2002-02-01 |
2010-11-17 |
ユーロ−セルティーク エス.エイ. |
疼痛の治療に有用な治療薬
|
US20050025791A1
(en)
*
|
2002-06-21 |
2005-02-03 |
Julius Remenar |
Pharmaceutical compositions with improved dissolution
|
US7790905B2
(en)
|
2002-02-15 |
2010-09-07 |
Mcneil-Ppc, Inc. |
Pharmaceutical propylene glycol solvate compositions
|
US7446107B2
(en)
*
|
2002-02-15 |
2008-11-04 |
Transform Pharmaceuticals, Inc. |
Crystalline forms of conazoles and methods of making and using the same
|
US7927613B2
(en)
|
2002-02-15 |
2011-04-19 |
University Of South Florida |
Pharmaceutical co-crystal compositions
|
AU2003213719A1
(en)
|
2002-03-01 |
2003-09-16 |
Regents Of The University Of Michigan |
Multiple-component solid phases containing at least one active pharmaceutical ingredient
|
US6962940B2
(en)
|
2002-03-20 |
2005-11-08 |
Celgene Corporation |
(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
|
US7893101B2
(en)
|
2002-03-20 |
2011-02-22 |
Celgene Corporation |
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
|
FR2843881B1
(fr)
*
|
2002-09-02 |
2006-06-02 |
Flamel Tech Sa |
Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
|
ATE419840T1
(de)
*
|
2002-04-09 |
2009-01-15 |
Flamel Tech Sa |
Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
|
ES2314227T7
(es)
*
|
2002-04-09 |
2012-11-19 |
Flamel Technologies |
Formulacion farmaceutica oral en forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de amoxilicina.
|
US7205413B2
(en)
*
|
2002-05-03 |
2007-04-17 |
Transform Pharmaceuticals, Inc. |
Solvates and polymorphs of ritonavir and methods of making and using the same
|
US20100129363A1
(en)
*
|
2002-05-17 |
2010-05-27 |
Zeldis Jerome B |
Methods and compositions using pde4 inhibitors for the treatment and management of cancers
|
US7323479B2
(en)
*
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
WO2003097052A2
(en)
|
2002-05-17 |
2003-11-27 |
Celgene Corporation |
Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
USRE48890E1
(en)
|
2002-05-17 |
2022-01-11 |
Celgene Corporation |
Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
|
EP1556033A4
(en)
|
2002-05-17 |
2006-05-31 |
Celgene Corp |
METHODS AND COMPOSITIONS USING CYTOKINE INHIBITOR SELECTIVE MEDICAMENTS FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES
|
EP1511490A4
(en)
*
|
2002-05-31 |
2009-03-11 |
Transform Pharmaceuticals Inc |
NOVEL CONAZOLE CRYSTALLINE FORMS AND RELATED METHODS, PHARMACEUTICAL COMPOSITIONS AND METHODS
|
US8829198B2
(en)
*
|
2007-10-31 |
2014-09-09 |
Proteotech Inc |
Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
|
US20070059356A1
(en)
*
|
2002-05-31 |
2007-03-15 |
Almarsson Oern |
Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
|
US6995168B2
(en)
*
|
2002-05-31 |
2006-02-07 |
Euro-Celtique S.A. |
Triazaspiro compounds useful for treating or preventing pain
|
JP4568603B2
(ja)
*
|
2002-05-31 |
2010-10-27 |
プロテオテック・インコーポレイテッド |
アミロイド疾患およびシヌクレイノパチー(例えばアルツハイマー病、タイプ2型糖尿病、およびパーキンソン病)を処置するための化合物、組成物、および方法
|
ATE548354T1
(de)
|
2002-07-24 |
2012-03-15 |
Ptc Therapeutics Inc |
Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen
|
CN1672186A
(zh)
*
|
2002-07-29 |
2005-09-21 |
皇家飞利浦电子股份有限公司 |
驱动等离子体显示板
|
DE60313478T2
(de)
|
2002-09-25 |
2008-01-03 |
Euro-Celtique S.A. |
N-substituierte hydromorphone und ihre anwendung
|
US20060135463A1
(en)
*
|
2002-09-27 |
2006-06-22 |
Wood Christopher B |
Methods and compositions for the treatment of lupus using clofarabine
|
CA2500360A1
(en)
*
|
2002-09-27 |
2004-04-08 |
Bioenvision, Inc. |
Methods and compositions for the treatment of autoimmune disorders using clofarabine
|
ZA200503024B
(en)
*
|
2002-10-15 |
2006-11-29 |
Celgene Corp |
Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
|
US11116782B2
(en)
|
2002-10-15 |
2021-09-14 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US7189740B2
(en)
*
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
US8404716B2
(en)
*
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US8404717B2
(en)
*
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
EP1900369A1
(en)
|
2002-10-15 |
2008-03-19 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
|
US20050203142A1
(en)
*
|
2002-10-24 |
2005-09-15 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
|
US20040087558A1
(en)
|
2002-10-24 |
2004-05-06 |
Zeldis Jerome B. |
Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
|
US7776907B2
(en)
*
|
2002-10-31 |
2010-08-17 |
Celgene Corporation |
Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
|
EP1569903A4
(en)
*
|
2002-11-06 |
2009-07-29 |
Celgene Corp |
METHOD FOR THE USE OF SELECTIVE CYTOKINE-INHIBITORY MEDICAMENTS FOR THE TREATMENT AND SUPERVISION OF MYELOPROLIFERATIVE DISEASES AND COMPOSITIONS CONTAINING THESE MEDICAMENTS
|
NZ564480A
(en)
|
2002-11-06 |
2008-12-24 |
Celgene Corp |
Use of selective cytokine inhibitory drugs for the treatment of Behcet's disease
|
US7563810B2
(en)
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
JP2006510617A
(ja)
*
|
2002-11-18 |
2006-03-30 |
セルジーン・コーポレーション |
(+)−3−(3,4−ジメトキシ−フェニル)−3−(1−オキソ−1,3−ジヒドロ−イソインドール−2−イル)−プロピオンアミドの使用方法およびそれを含む組成物
|
BR0316256A
(pt)
*
|
2002-11-18 |
2005-10-04 |
Celgene Corp |
Métodos de inibir a produção de tnf-alfa e a atividade de pde4, de tratar ou prevenir uma doença ou um distúrbio, de controlar os nìveis de camp em uma célula e de produzir um composto, composição farmacêutica e composto
|
US7202259B2
(en)
*
|
2002-11-18 |
2007-04-10 |
Euro-Celtique S.A. |
Therapeutic agents useful for treating pain
|
US6864251B2
(en)
|
2002-12-03 |
2005-03-08 |
Vela Pharmaceuticals, Inc. |
Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines
|
EP2218779A1
(en)
|
2002-12-16 |
2010-08-18 |
Halozyme, Inc. |
Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof
|
US7582635B2
(en)
|
2002-12-24 |
2009-09-01 |
Purdue Pharma, L.P. |
Therapeutic agents useful for treating pain
|
EP2339328A3
(en)
|
2002-12-30 |
2011-07-13 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical co-crystal compositions of celecoxib
|
US8183290B2
(en)
|
2002-12-30 |
2012-05-22 |
Mcneil-Ppc, Inc. |
Pharmaceutically acceptable propylene glycol solvate of naproxen
|
EP1608339B8
(en)
|
2003-02-28 |
2012-04-25 |
McNeill-PPC, Inc. |
Pharmaceutical co-crystal of celecoxib-nicotinamide
|
US20090123367A1
(en)
*
|
2003-03-05 |
2009-05-14 |
Delfmems |
Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
|
CA2517145C
(en)
|
2003-03-05 |
2017-08-01 |
Halozyme, Inc. |
Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
US20040186180A1
(en)
|
2003-03-21 |
2004-09-23 |
Gelotte Cathy K. |
Non-steroidal anti-inflammatory drug dosing regimen
|
US20040214893A1
(en)
*
|
2003-04-11 |
2004-10-28 |
Matthew Peterson |
Gabapentin compositions
|
ES2770035T3
(es)
|
2003-04-11 |
2020-06-30 |
Ptc Therapeutics Inc |
Compuesto de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades
|
US20050239088A1
(en)
*
|
2003-05-16 |
2005-10-27 |
Shepard H M |
Intron fusion proteins, and methods of identifying and using same
|
JP2007502329A
(ja)
*
|
2003-05-23 |
2007-02-08 |
トランスフォーム・ファーマシューティカルズ・インコーポレイテッド |
セルトラリン組成物
|
US20100331380A1
(en)
*
|
2009-06-29 |
2010-12-30 |
Esposito Luke A |
Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies
|
US8916598B2
(en)
|
2003-05-30 |
2014-12-23 |
Proteotech Inc |
Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies
|
US20090227647A1
(en)
*
|
2008-03-05 |
2009-09-10 |
Thomas Lake |
Compounds, Compositions and Methods for the Treatment of Islet Amyloid Polypeptide (IAPP) Accumulation in Diabetes
|
US7438903B2
(en)
*
|
2003-06-06 |
2008-10-21 |
Nbty, Inc. |
Methods and compositions that enhance bioavailability of coenzyme-Q10
|
CN1319955C
(zh)
*
|
2003-06-10 |
2007-06-06 |
浙江海正药业股份有限公司 |
莫吉斯坦晶型
|
MY142655A
(en)
*
|
2003-06-12 |
2010-12-15 |
Euro Celtique Sa |
Therapeutic agents useful for treating pain
|
WO2005007641A1
(en)
*
|
2003-07-03 |
2005-01-27 |
Euro-Celtique S.A. |
2-pyridine alkyne derivatives useful for treating pain
|
US20050009782A1
(en)
*
|
2003-07-09 |
2005-01-13 |
Comper Wayne D. |
Antiviral charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and methods of use thereof
|
CA2533594C
(en)
*
|
2003-07-23 |
2013-04-02 |
Synta Pharmaceuticals, Corp. |
Compounds for inflammation and immune-related uses
|
CN101935315A
(zh)
|
2003-07-24 |
2011-01-05 |
欧洲凯尔蒂克公司 |
用于治疗或预防疼痛的杂芳基-四氢哌啶基化合物
|
UA84710C2
(ru)
|
2003-07-24 |
2008-11-25 |
Евро-Селтик С.А. |
Пиперидиновые производные, фармацевтическая композиция, которая их содержит, и способ лечения
|
EP1867644B1
(en)
|
2003-07-24 |
2009-05-20 |
Euro-Celtique S.A. |
Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
|
SI1942106T1
(sl)
*
|
2003-08-01 |
2012-01-31 |
Euro Celtique Sa |
Terapevtska sredstva, uporabna za zdravljenje bolečine
|
AU2004268383A1
(en)
*
|
2003-09-03 |
2005-03-10 |
Agi Therapeutics Limited |
Proton pump inhibitor formulations, and methods of preparing and using such formulations
|
UA83504C2
(en)
|
2003-09-04 |
2008-07-25 |
Селджин Корпорейшн |
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
DK1664041T3
(da)
|
2003-09-22 |
2008-10-27 |
Euro Celtique Sa |
Phenylcarboxamidforbindelser, der er egnede til behandling af smerter
|
SI1664016T1
(sl)
*
|
2003-09-22 |
2009-04-30 |
Euro Celtique Sa |
Terapevtska sredstva, uporabna za zdravljenje bolečine
|
US7612096B2
(en)
*
|
2003-10-23 |
2009-11-03 |
Celgene Corporation |
Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
|
US20050113410A1
(en)
*
|
2003-11-03 |
2005-05-26 |
Mark Tawa |
Pharmaceutical salts of zafirlukast
|
JP2007510670A
(ja)
*
|
2003-11-06 |
2007-04-26 |
セルジーン・コーポレーション |
サリドマイドを用いた、癌、及び他の疾患を治療、及び管理する方法ならびに組成物
|
US7470435B2
(en)
*
|
2003-11-17 |
2008-12-30 |
Andrx Pharmaceuticals, Llc |
Extended release venlafaxine formulation
|
EP1692128A1
(en)
|
2003-11-19 |
2006-08-23 |
Signal Pharmaceuticals LLC |
Indazole compounds and methods of use thereof as protein kinase inhibitors
|
WO2005051298A2
(en)
|
2003-11-19 |
2005-06-09 |
Metabasis Therapeutics, Inc. |
Novel phosphorus-containing thyromimetics
|
KR100589357B1
(ko)
*
|
2003-11-27 |
2006-06-14 |
삼성에스디아이 주식회사 |
형광체 도포에 적합한 플라즈마 디스플레이 패널
|
EA200601249A1
(ru)
*
|
2003-12-30 |
2007-02-27 |
Еуро-Селтик С. А. |
Пиперазины, пригодные для лечения боли
|
EP2292213A1
(en)
|
2004-02-06 |
2011-03-09 |
Cephalon, Inc. |
Compositions comprising a polymorphic form of armodafinil
|
JP2007522203A
(ja)
*
|
2004-02-11 |
2007-08-09 |
アスファーマ・リミテッド |
時間療法用組成物とそれらの使用方法
|
ATE397924T1
(de)
|
2004-02-18 |
2008-07-15 |
Gpc Biotech Ag |
Satraplatin zur behandlung von resistenten oder refrkatären tumoren
|
CN1956718A
(zh)
|
2004-03-22 |
2007-05-02 |
细胞基因公司 |
用于治疗和控制皮肤疾病和病症的含免疫调节化合物的组合物和使用方法
|
WO2005092065A2
(en)
*
|
2004-03-25 |
2005-10-06 |
Transform Pharmaceuticals, Inc. |
Novel tricyclic compounds and related methods of treatment
|
CA2563207A1
(en)
*
|
2004-04-14 |
2005-11-24 |
Celgene Corporation |
Use of selective cytokine inhibitory drugs in myelodysplastic syndromes
|
MXPA06011798A
(es)
*
|
2004-04-14 |
2007-01-16 |
Celgene Corp |
Metodos de uso y composiciones que comprenden compuestos inmunomoduladores para el tratamiento y manejo de sindromes mielodisplasticos.
|
ZA200609228B
(en)
*
|
2004-04-23 |
2008-05-28 |
Celgene Corp |
Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension
|
US7351739B2
(en)
*
|
2004-04-30 |
2008-04-01 |
Wellgen, Inc. |
Bioactive compounds and methods of uses thereof
|
KR20050105411A
(ko)
*
|
2004-05-01 |
2005-11-04 |
삼성에스디아이 주식회사 |
플라즈마 디스플레이 패널
|
US7803366B2
(en)
*
|
2004-05-07 |
2010-09-28 |
Nbty, Inc. |
Methods and compositions that enhance bioavailability of coenzyme-Q10
|
JP2008506366A
(ja)
*
|
2004-05-14 |
2008-03-06 |
レセプター バイオロジックス インコーポレイテッド |
細胞表面受容体アイソフォームならびにその同定および使用方法
|
ATE483455T1
(de)
|
2004-05-28 |
2010-10-15 |
Transform Pharmaceuticals Inc |
Mischkristalle sowie sie enthaltende pharmazeutische zusammensetzungen
|
WO2005120584A2
(en)
*
|
2004-06-03 |
2005-12-22 |
The Trustees Of Columbia University In The City Of New York |
Radiolabeled arylsulfonyl compounds and uses thereof
|
JP5017103B2
(ja)
*
|
2004-06-17 |
2012-09-05 |
トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド |
薬剤共結晶組成物および関連した使用方法
|
US20080126195A1
(en)
|
2004-07-22 |
2008-05-29 |
Ritter Andrew J |
Methods and Compositions for Treating Lactose Intolerance
|
US20090042979A1
(en)
*
|
2004-08-06 |
2009-02-12 |
Transform Pharmaceuticals Inc. |
Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
|
JP2008509154A
(ja)
*
|
2004-08-06 |
2008-03-27 |
トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド |
新規なスタチン薬剤組成物および関連治療方法
|
NZ552390A
(en)
*
|
2004-08-06 |
2010-01-29 |
Transform Pharmaceuticals Inc |
Novel fenofibrate formulations and related methods of treatment
|
ATE531367T1
(de)
|
2004-09-17 |
2011-11-15 |
Whitehead Biomedical Inst |
Verbindungen, zusammensetzungen und verfahren zur verhinderung einer a-synuklein-vergiftung
|
TW200621232A
(en)
|
2004-09-21 |
2006-07-01 |
Synta Pharmaceuticals Corp |
Compounds for inflammation and immune-related uses
|
AU2005302523A1
(en)
*
|
2004-10-28 |
2006-05-11 |
Celgene Corporation |
Methods and compositions using PDE4 modulators for treatment and management of central nervous system injury
|
US20080160099A1
(en)
*
|
2004-11-10 |
2008-07-03 |
The Trustees Of Columbia University In The City Of New York |
Methods For Treating or Preventing a Vascular Disease
|
ES2594874T3
(es)
|
2004-11-18 |
2016-12-23 |
Synta Pharmaceuticals Corp. |
Compuestos de triazol que modulan la actividad de HSP90
|
EP1831235B1
(en)
|
2004-12-16 |
2013-02-20 |
The Regents of The University of California |
Lung-targeted drugs
|
PL2561872T3
(pl)
|
2004-12-17 |
2015-03-31 |
Anadys Pharmaceuticals Inc |
3,5-Dipodstawione oraz 3,5,7-tripodstawione związki 3H-oksazolo[4,5-d]pirymidyn-2-onowe i ich proleki
|
ATE432921T1
(de)
|
2004-12-23 |
2009-06-15 |
Gpc Biotech Ag |
Quadratsäurederivate mit antiproliferativer wirkung
|
US20060160783A1
(en)
*
|
2004-12-30 |
2006-07-20 |
Transform Pharmaceuticals, Inc. |
Novel omeprazole forms and related methods
|
KR20070107022A
(ko)
*
|
2005-01-07 |
2007-11-06 |
신타 파마슈티칼스 코프. |
염증 및 면역 관련 용도를 위한 화합물
|
CA2595855C
(en)
|
2005-01-25 |
2017-07-04 |
Synta Pharmaceuticals Corp. |
Pyrazine compounds for inflammation and immune-related uses
|
US8318210B2
(en)
*
|
2005-02-28 |
2012-11-27 |
Neos Therapeutics, Lp |
Compositions and methods of making sustained release liquid formulations
|
US20060216355A1
(en)
*
|
2005-03-28 |
2006-09-28 |
Donald Spector |
Encapsulated pharmaceuticals in a medium having non-encapsulated flavoring agents
|
US20090156545A1
(en)
*
|
2005-04-01 |
2009-06-18 |
Hostetler Karl Y |
Substituted Phosphate Esters of Nucleoside Phosphonates
|
ATE534652T1
(de)
|
2005-04-01 |
2011-12-15 |
Univ California |
Phosphono-pent-2-en-1-yl-nukleoside und analoga
|
JP2008539731A
(ja)
|
2005-05-02 |
2008-11-20 |
コールド スプリング ハーバー ラボラトリー |
癌の診断及び治療のための組成物及び方法
|
WO2006119510A2
(en)
*
|
2005-05-04 |
2006-11-09 |
Receptor Biologix, Inc. |
Isoforms of receptor for advanced glycation end products (rage) and methods of identifying and using same
|
US20070041944A1
(en)
*
|
2005-05-05 |
2007-02-22 |
The Trustees Of Columbia University In The City Of New York |
Treating tumors by ENH dislocation of ID proteins
|
US20090170769A1
(en)
*
|
2005-05-13 |
2009-07-02 |
Pei Jin |
Cell surface receptor isoforms and methods of identifying and using the same
|
US20060270707A1
(en)
*
|
2005-05-24 |
2006-11-30 |
Zeldis Jerome B |
Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
|
US20070054868A1
(en)
*
|
2005-06-20 |
2007-03-08 |
The Trustees Of Columbia University In The City Of New York |
Synergistic polyphenol compounds, compositions thereof, and uses thereof
|
WO2007002109A2
(en)
*
|
2005-06-20 |
2007-01-04 |
The Regents Of The University Of California |
Multidentate pyrone-derived chelators for medicinal imaging and chelation
|
MX2008000249A
(es)
*
|
2005-07-06 |
2008-03-18 |
Sepracor Inc |
Combinaciones de eszopiclona y o-desmetilvenlafaxina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y cognitivos.
|
CA2615718A1
(en)
|
2005-07-22 |
2007-02-01 |
Amgen Inc. |
Aniline sulfonamide derivatives and their uses
|
US20080058282A1
(en)
|
2005-08-30 |
2008-03-06 |
Fallon Joan M |
Use of lactulose in the treatment of autism
|
ES2434946T3
(es)
|
2005-08-31 |
2013-12-18 |
Celgene Corporation |
Compuestos de isoindol imida y composiciones que los comprenden y métodos para usarlo
|
US20070066512A1
(en)
|
2005-09-12 |
2007-03-22 |
Dominique Verhelle |
Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
|
US20080138295A1
(en)
*
|
2005-09-12 |
2008-06-12 |
Celgene Coporation |
Bechet's disease using cyclopropyl-N-carboxamide
|
WO2008051197A2
(en)
*
|
2005-09-20 |
2008-05-02 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
US20070092553A1
(en)
*
|
2005-10-21 |
2007-04-26 |
Pfab Lp |
Compositions and methods of making rapidly dissolving lonically masked formulations
|
EP2298770A1
(en)
|
2005-11-03 |
2011-03-23 |
ChemBridge Corporation |
Heterocyclic compounds as TrkA modulators
|
EP2289497A1
(en)
|
2005-11-10 |
2011-03-02 |
Circ Pharma Research and Development Limited |
Once-daily administration of central nervous system drugs
|
CA2628928A1
(en)
*
|
2005-11-10 |
2007-05-24 |
Receptor Biologix, Inc. |
Hepatocyte growth factor intron fusion proteins
|
BRPI0619679A2
(pt)
|
2005-11-21 |
2011-10-11 |
Purdue Pharma Lp |
compostos 4-oxadiazolil-piperidina e seus usos
|
US8138361B2
(en)
*
|
2005-12-28 |
2012-03-20 |
The Trustees Of The University Of Pennsylvania |
C-10 carbamates of taxanes
|
US20070155791A1
(en)
*
|
2005-12-29 |
2007-07-05 |
Zeldis Jerome B |
Methods for treating cutaneous lupus using aminoisoindoline compounds
|
CA2841386A1
(en)
*
|
2005-12-30 |
2007-07-12 |
Zensun (Shanghai) Science & Technology Limited |
Extended release of neuregulin for improved cardiac function
|
JP2009528273A
(ja)
|
2006-01-25 |
2009-08-06 |
シンタ ファーマシューティカルズ コーポレーション |
炎症および免疫関連使用用の置換ビアリール化合物
|
WO2007087427A2
(en)
*
|
2006-01-25 |
2007-08-02 |
Synta Pharmaceuticals Corp. |
Thiazole and thiadiazole compounds for inflammation and immune-related uses
|
US7816535B2
(en)
|
2006-01-25 |
2010-10-19 |
Synta Pharmaceuticals Corp. |
Vinyl-phenyl derivatives for inflammation and immune-related uses
|
ES2403368T3
(es)
|
2006-01-31 |
2013-05-17 |
Synta Pharmaceuticals Corporation |
Compuestos de piridilfenilo para la inflamación y usos inmunorrelacionados
|
US7518017B2
(en)
|
2006-02-17 |
2009-04-14 |
Idexx Laboratories |
Fenicol compounds and methods synthesizing 2-trifluoroacetamido-3-substituted propiophenone compounds
|
WO2007106494A2
(en)
*
|
2006-03-13 |
2007-09-20 |
Encysive Pharmaceuticals, Inc. |
Methods and compositions for treatment of diastolic heart failure
|
RU2008136315A
(ru)
*
|
2006-03-13 |
2010-04-20 |
Инсайсив Фармасьютикалз, Инк. (US) |
Композиции ситаксентана натрия
|
ES2427247T3
(es)
*
|
2006-03-13 |
2013-10-30 |
Kyorin Pharmaceutical Co., Ltd. |
Aminoquinolonas como inhibidores de GSK-3
|
JP2009531443A
(ja)
*
|
2006-03-29 |
2009-09-03 |
フォールドアールエックス ファーマシューティカルズ インコーポレーティッド |
α−シヌクレイン毒性の抑制
|
US7659287B2
(en)
*
|
2006-06-08 |
2010-02-09 |
Amgen Inc. |
Benzamide derivatives and uses related thereto
|
TW200808695A
(en)
*
|
2006-06-08 |
2008-02-16 |
Amgen Inc |
Benzamide derivatives and uses related thereto
|
AU2007257683A1
(en)
*
|
2006-06-12 |
2007-12-21 |
Symphogen A/S |
Pan-cell surface receptor- specific therapeutics
|
CN101501039B
(zh)
|
2006-06-22 |
2012-02-22 |
安那迪斯药品股份有限公司 |
吡咯并[1,2-b]哒嗪酮化合物
|
JP5345527B2
(ja)
|
2006-06-22 |
2013-11-20 |
アナディス ファーマシューティカルズ インク |
プロドラッグである5−アミノ−3−(3’−デオキシ−β−D−リボフラノシル)−チアゾロ[4,5−d]ピリミジン−2,7−ジオン
|
US20080026061A1
(en)
*
|
2006-06-22 |
2008-01-31 |
Reichwein John F |
Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
|
KR101778174B1
(ko)
*
|
2006-07-05 |
2017-09-13 |
카탈리스트 바이오사이언시즈, 인코포레이티드 |
프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제
|
US8637469B2
(en)
|
2006-07-11 |
2014-01-28 |
Roy C. Levitt |
Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
|
EP2040712B1
(en)
|
2006-07-18 |
2011-03-02 |
Anadys Pharmaceuticals, Inc. |
Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines
|
CL2007002218A1
(es)
*
|
2006-08-03 |
2008-03-14 |
Celgene Corp Soc Organizada Ba |
Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
|
CA2659037A1
(en)
*
|
2006-08-04 |
2008-03-13 |
Agi Therapeutics Research Limited |
Methods for treating at least one condition having mt1 receptor, 5ht2b receptor, and l-type calcium channel activity
|
US8063225B2
(en)
|
2006-08-14 |
2011-11-22 |
Chembridge Corporation |
Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
|
US9114133B2
(en)
|
2006-08-25 |
2015-08-25 |
U.S. Dept. Of Veterans Affairs |
Method of improving diastolic dysfunction
|
US8877780B2
(en)
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
WO2008027542A2
(en)
|
2006-08-30 |
2008-03-06 |
Celgene Corporation |
5-substituted isoindoline compounds
|
US7879846B2
(en)
|
2006-09-21 |
2011-02-01 |
Kyorin Pharmaceutical Co.., Ltd. |
Serine hydrolase inhibitors
|
DK2420497T3
(en)
|
2006-09-26 |
2016-03-07 |
Celgene Corp |
5-substituted quinazolinone derivatives as anticancer agents
|
US8779154B2
(en)
|
2006-09-26 |
2014-07-15 |
Qinglin Che |
Fused ring compounds for inflammation and immune-related uses
|
CA2665841C
(en)
|
2006-10-09 |
2016-04-05 |
Charleston Laboratories, Inc. |
Pharmaceutical compositions
|
EP1914234A1
(en)
*
|
2006-10-16 |
2008-04-23 |
GPC Biotech Inc. |
Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
|
EP2617423A1
(en)
|
2006-10-19 |
2013-07-24 |
Genzyme Corporation |
Purine derivatives for the treatment of cystic diseases
|
US20080103189A1
(en)
|
2006-10-19 |
2008-05-01 |
Auspex Pharmaceuticals, Inc. |
Preparation and utility of substituted indoles
|
WO2008057604A2
(en)
*
|
2006-11-08 |
2008-05-15 |
The Regents Of The University Of California |
Small molecule therapeutics, syntheses of analogues and derivatives and methods of use
|
JP5538894B2
(ja)
|
2006-11-13 |
2014-07-02 |
シンタ ファーマシューティカルズ コーポレーション |
炎症及び免疫関連使用のためのシクロヘキセニル−アリール化合物
|
EP2091527B1
(en)
|
2006-12-13 |
2016-03-23 |
Temple University - Of The Commonwealth System of Higher Education |
Sulfide, sulfoxide and sulfone chalcone analogues, derivatives thereof and therapeutic uses thereof
|
JP2010513530A
(ja)
*
|
2006-12-22 |
2010-04-30 |
エンサイシブ・ファーマシューティカルズ・インコーポレイテッド |
C3a受容体の調節剤およびその使用方法
|
CA2673586A1
(en)
*
|
2006-12-26 |
2008-07-24 |
Amgen Inc. |
N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases
|
CN101595100B
(zh)
|
2007-01-16 |
2014-06-11 |
普渡制药公司 |
作为orl-1配体的杂环取代的哌啶
|
FR2911506B1
(fr)
*
|
2007-01-18 |
2009-07-03 |
Ceva Sante Animale Sa |
Compositions pharmaceutiques destinees a une administration par voie orale sous forme de suspensions aqueuses stabilisees
|
US8999395B2
(en)
|
2007-02-09 |
2015-04-07 |
Ceva Sante Animale |
Pharmaceutical compositions for oral administration in the form of stabilised aqueous suspensions
|
ES2720430T3
(es)
|
2007-02-09 |
2019-07-22 |
Metabasis Therapeutics Inc |
Antagonistas novedosos del receptor de glucagón
|
JP5666140B2
(ja)
|
2007-02-21 |
2015-02-12 |
サノヴィオン ファーマシューティカルズ インコーポレーテッド |
(−)−o−デスメチルベンラファキシンを含む固形物およびそれらの使用
|
WO2008106167A1
(en)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
|
EP2144604B1
(en)
|
2007-02-28 |
2011-09-21 |
Conatus Pharmaceuticals, Inc. |
Methods for the treatment of chronic viral hepatitis C using RO 113-0830
|
PL2125698T3
(pl)
|
2007-03-15 |
2017-03-31 |
Auspex Pharmaceuticals, Inc. |
Deuterowana wenlafaksyna-d9
|
PT2079456E
(pt)
|
2007-04-04 |
2013-03-13 |
Sigmoid Pharma Ltd |
Composições farmacêuticas de ciclosporina
|
WO2008132707A1
(en)
|
2007-04-26 |
2008-11-06 |
Sigmoid Pharma Limited |
Manufacture of multiple minicapsules
|
CA2833209C
(en)
*
|
2007-04-27 |
2016-06-28 |
Purdue Pharma L.P. |
Piperidine and piperazine compounds as trpv1 antagonists
|
EP2091936B1
(en)
*
|
2007-04-27 |
2013-05-15 |
Purdue Pharma LP |
Therapeutic agents useful for treating pain
|
US7892776B2
(en)
|
2007-05-04 |
2011-02-22 |
The Regents Of The University Of California |
Screening assay to identify modulators of protein kinase A
|
EP2019101A1
(en)
*
|
2007-07-26 |
2009-01-28 |
GPC Biotech AG |
Pyrazol[3,4-d]pyrimidin-4-one useful as Kinase Inhibitor
|
NZ580429A
(en)
|
2007-05-31 |
2012-04-27 |
Sepracor Inc |
Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
|
EP2581081A3
(en)
|
2007-06-01 |
2013-07-31 |
The Trustees Of Princeton University |
Treatment of viral infections by modulation of host cell metabolic pathways
|
WO2009011988A2
(en)
*
|
2007-06-05 |
2009-01-22 |
Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University |
Cyclodepsipeptides with antineoplastic activity and methods of using to inhibit cancer and microbial growth
|
US20090042987A1
(en)
*
|
2007-07-06 |
2009-02-12 |
Michael Lionel Selley |
Treatment of neuropathic pain
|
EP2170062A4
(en)
*
|
2007-07-12 |
2010-12-29 |
Tragara Pharmaceuticals Inc |
METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER DISORDERS, TUMORS AND TUMOR-DISORDED DISEASES
|
WO2009012263A2
(en)
*
|
2007-07-18 |
2009-01-22 |
The Trustees Of Columbia University In The City Of New York |
Tissue-specific micrornas and compositions and uses thereof
|
US8435996B2
(en)
|
2007-08-01 |
2013-05-07 |
Synta Pharmaceuticals Corp. |
Heterocycle-aryl compounds for inflammation and immune-related uses
|
CA2695156A1
(en)
|
2007-08-01 |
2009-02-05 |
Synta Pharmaceuticals Corp. |
Vinyl-aryl derivatives for inflammation and immune-related uses
|
WO2009020590A1
(en)
|
2007-08-07 |
2009-02-12 |
Celgene Corporation |
Methods for treating lymphomas in certain patient populations and screening patients for said therapy
|
CN106279283A
(zh)
|
2007-08-13 |
2017-01-04 |
症变治疗公司 |
新颖的葡糖激酶活化剂
|
US20090062242A1
(en)
*
|
2007-08-28 |
2009-03-05 |
Agi Therapeutics Plc |
Methods and compositions for treating gastrointestinal conditions
|
EP3564240B1
(en)
*
|
2007-08-31 |
2022-04-06 |
Purdue Pharma L.P. |
Piperidine intermediates
|
ES2371800T3
(es)
*
|
2007-09-11 |
2012-01-10 |
Kyorin Pharmaceutical Co.,Ltd. |
Cianoaminoquinolonas como inhibidores de gsk-3.
|
BRPI0816814B1
(pt)
|
2007-09-12 |
2021-08-31 |
Kyorin Pharmaceutical Co. Ltd |
Composto, composição farmacêutica e uso de um composto
|
WO2009042177A1
(en)
|
2007-09-26 |
2009-04-02 |
Celgene Corporation |
6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
|
US20090264421A1
(en)
*
|
2007-10-05 |
2009-10-22 |
Bible Keith C |
Methods and Compositions for Treating Cancer
|
BRPI0818033A2
(pt)
*
|
2007-10-16 |
2015-03-24 |
Symphogen As |
Composições compreendendo multímeros otimizados de her1 e her3 e métodos para usos dos mesmos
|
US20110009463A1
(en)
*
|
2007-10-17 |
2011-01-13 |
Yuri Karl Petersson |
Geranylgeranyl transferase inhibitors and methods of making and using the same
|
CA2702494A1
(en)
|
2007-10-19 |
2009-04-23 |
The Regents Of The University Of California |
Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss
|
WO2009079375A1
(en)
|
2007-12-14 |
2009-06-25 |
Georgetown University |
Histone deacetylase inhibitors
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
JP5714910B2
(ja)
|
2008-01-09 |
2015-05-07 |
チャールストン ラボラトリーズ,インコーポレイテッド |
薬学的組成物
|
TWI395593B
(zh)
|
2008-03-06 |
2013-05-11 |
Halozyme Inc |
可活化的基質降解酵素之活體內暫時性控制
|
US8658163B2
(en)
|
2008-03-13 |
2014-02-25 |
Curemark Llc |
Compositions and use thereof for treating symptoms of preeclampsia
|
HUE032873T2
(en)
|
2008-03-17 |
2017-11-28 |
Ambit Biosciences Corp |
1- (3- (6,7-Dimethoxyquinazolin-4-yloxy) phenyl) -3- (5- (1,1,1-trifluoro-2-methylpropan-2-yl) isoxazol-3-yl) urea as RAF kinase inhibitor for the treatment of cancer
|
US8822500B2
(en)
|
2008-03-19 |
2014-09-02 |
Chembridge Corporation |
Tyrosine kinase inhibitors
|
MX2010010272A
(es)
|
2008-03-19 |
2011-05-25 |
Chembridge Corp |
Nuevos inhibidores de tirosina quinasa.
|
US9249147B2
(en)
|
2008-03-19 |
2016-02-02 |
Chembridge Corporation |
Tyrosine kinase inhibitors
|
EP2687213B1
(en)
|
2008-03-27 |
2019-01-23 |
Celgene Corporation |
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
|
RU2471782C2
(ru)
|
2008-03-27 |
2013-01-10 |
Селджин Корпорейшн |
Твердые формы, содержащие (+)-2-[1-(3-этокси-4-метоксифенил)-2-метилсульфонилэтил]-4-ацетиламиноизоиндолин-1, 3-дион, их композиции и применение
|
AU2009236635B2
(en)
|
2008-04-14 |
2014-02-13 |
Halozyme, Inc. |
Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
|
US8084025B2
(en)
|
2008-04-18 |
2011-12-27 |
Curemark Llc |
Method for the treatment of the symptoms of drug and alcohol addiction
|
EP2112152A1
(en)
|
2008-04-22 |
2009-10-28 |
GPC Biotech AG |
Dihydropteridinones as Plk Inhibitors
|
EP2112150B1
(en)
|
2008-04-22 |
2013-10-16 |
Forma Therapeutics, Inc. |
Improved raf inhibitors
|
US9314469B2
(en)
|
2008-05-05 |
2016-04-19 |
Tonix Pharma Holdings Limited |
Method for treating neurocognitive dysfunction
|
WO2009139880A1
(en)
*
|
2008-05-13 |
2009-11-19 |
Celgene Corporation |
Thioxoisoindoline compounds and compositions and methods of using the same
|
RU2010151944A
(ru)
*
|
2008-05-20 |
2012-06-27 |
Серенис Терапьютикс С.А. (Fr) |
Ниацин и нспвс для комбинированной терапии
|
PL2318035T3
(pl)
|
2008-07-01 |
2019-10-31 |
Curemark Llc |
Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
|
TW201004632A
(en)
|
2008-07-02 |
2010-02-01 |
Idenix Pharmaceuticals Inc |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
AU2009275218C1
(en)
|
2008-07-21 |
2015-02-05 |
Purdue Pharma L.P. |
Substituted-Quinoxaline-Type Bridged-Piperidine Compounds and the uses thereof
|
PT2326651E
(pt)
|
2008-07-30 |
2014-02-12 |
Purdue Pharma Lp |
Análogos de buprenorfina
|
US8907103B2
(en)
|
2008-08-13 |
2014-12-09 |
Metabasis Therapeutics, Inc. |
Glucagon antagonists
|
EP2348863A4
(en)
|
2008-09-04 |
2012-03-07 |
Anacor Pharmaceuticals Inc |
BORN SMALL MOLECULES
|
EP2340254B8
(en)
|
2008-09-15 |
2014-05-21 |
Biovista, Inc. |
Compositions and methods for treating epilepsy
|
EP2350064A1
(en)
*
|
2008-10-01 |
2011-08-03 |
Synta Pharmaceuticals Corp. |
Compounds for inflammation and immune-related uses
|
WO2010042834A1
(en)
|
2008-10-09 |
2010-04-15 |
Anadys Pharmaceuticals, Inc. |
A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
|
JP2012505241A
(ja)
*
|
2008-10-10 |
2012-03-01 |
パーデュー・リサーチ・ファウンデーション |
アルツハイマー病の治療用組成物
|
US8703962B2
(en)
*
|
2008-10-24 |
2014-04-22 |
Purdue Pharma L.P. |
Monocyclic compounds and their use as TRPV1 ligands
|
US8759362B2
(en)
*
|
2008-10-24 |
2014-06-24 |
Purdue Pharma L.P. |
Bicycloheteroaryl compounds and their use as TRPV1 ligands
|
US8546388B2
(en)
*
|
2008-10-24 |
2013-10-01 |
Purdue Pharma L.P. |
Heterocyclic TRPV1 receptor ligands
|
PE20140963A1
(es)
|
2008-10-29 |
2014-08-06 |
Celgene Corp |
Compuestos de isoindolina para el tratamiento de cancer
|
JP2012509352A
(ja)
*
|
2008-11-20 |
2012-04-19 |
パーデュー・リサーチ・ファウンデーション |
Bace1のキナゾリン阻害剤および使用方法
|
US8859590B2
(en)
|
2008-12-05 |
2014-10-14 |
Purdue Research Foundation |
Inhibitors of BACE1 and methods for treating Alzheimer's disease
|
CN102307993B
(zh)
|
2008-12-09 |
2014-06-25 |
哈洛齐梅公司 |
延长的可溶性ph20多肽及其用途
|
CN105384676B
(zh)
|
2008-12-16 |
2019-05-07 |
桑诺维恩药品公司 |
三重再摄取抑制剂及其应用方法
|
EP2379073A2
(en)
|
2008-12-22 |
2011-10-26 |
Sloan Kettering Institute For Cancer Research |
Methods for treating or preventing cancer and neurodegenerative diseases
|
AU2009330124A1
(en)
|
2008-12-22 |
2011-07-14 |
Sloan-Kettering Institute For Cancer Research |
Coumarin-based compounds for the treatment of Alzheimer's disease and cancer
|
CN102307892A
(zh)
|
2008-12-31 |
2012-01-04 |
西尼克斯公司 |
环孢菌素a的衍生物
|
CN105031628B
(zh)
|
2009-01-06 |
2020-10-02 |
加尔纳根有限责任公司 |
治疗或预防大肠杆菌导致的经口感染的组合物和方法
|
KR20170005192A
(ko)
|
2009-01-06 |
2017-01-11 |
큐어론 엘엘씨 |
스타필로코쿠스 아우레우스 감염의 치료 또는 예방 및 표면 상의 스타필로코쿠스 아우레우스의 박멸 또는 감소를 위한 조성물 및 방법
|
WO2010088450A2
(en)
|
2009-01-30 |
2010-08-05 |
Celladon Corporation |
Methods for treating diseases associated with the modulation of serca
|
US8389559B2
(en)
|
2009-02-09 |
2013-03-05 |
Sunovion Pharmaceuticals Inc. |
Pyrrolidine triple reuptake inhibitors
|
AU2010213936B2
(en)
|
2009-02-10 |
2014-07-31 |
Celgene Corporation |
Methods of using and compositions comprising PDE4 modulators for treatment, prevention and management of tuberculosis
|
US8568793B2
(en)
|
2009-02-11 |
2013-10-29 |
Hope Medical Enterprises, Inc. |
Sodium nitrite-containing pharmaceutical compositions
|
EP2396327A1
(en)
|
2009-02-11 |
2011-12-21 |
Sunovion Pharmaceuticals Inc. |
Histamine h3 inverse agonists and antagonists and methods of use thereof
|
WO2010093434A1
(en)
|
2009-02-11 |
2010-08-19 |
Celgene Corporation |
Isotopologues of lenalidomide
|
KR20110124780A
(ko)
|
2009-02-24 |
2011-11-17 |
리터 파마슈티컬즈 인코오포레이티드 |
프리바이오틱 제제 및 사용 방법
|
EP2448406B1
(en)
|
2009-02-26 |
2016-04-20 |
Relmada Therapeutics, Inc. |
Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
|
ES2456275T3
(es)
|
2009-02-27 |
2014-04-21 |
Ambit Biosciences Corporation |
Derivados de quinazolina moduladores de la quinasa JAK y su uso en métodos
|
JP5690286B2
(ja)
|
2009-03-04 |
2015-03-25 |
イデニク プハルマセウティカルス,インコーポレイテッド |
ホスホチオフェン及びホスホチアゾールhcvポリメラーゼ阻害剤
|
EP2403523A1
(en)
|
2009-03-06 |
2012-01-11 |
Halozyme, Inc. |
Temperature sensitive mutants of matrix metalloprotease 1 und uses thereof
|
WO2010104205A1
(en)
*
|
2009-03-11 |
2010-09-16 |
Kyorin Pharmaceutical Co., Ltd. |
7-cycloalkylaminoquinolones as gsk-3 inhibitors
|
CA2754909A1
(en)
|
2009-03-11 |
2010-09-16 |
Ambit Biosciences Corp. |
Combination of an indazolylaminopyrrolotriazine and taxane for cancer treatment
|
WO2010110686A1
(en)
|
2009-03-27 |
2010-09-30 |
Pathway Therapeutics Limited |
Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
|
CA2756067A1
(en)
|
2009-03-27 |
2010-09-30 |
Pathway Therapeutics, Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
US9056050B2
(en)
|
2009-04-13 |
2015-06-16 |
Curemark Llc |
Enzyme delivery systems and methods of preparation and use
|
AR076341A1
(es)
|
2009-04-20 |
2011-06-01 |
Elcelyx Therapeutics Inc |
Terapias basadas en ligados de receptores quimiosensoriales. metodo de tratamiento. composicion
|
AU2010239341B2
(en)
|
2009-04-22 |
2015-07-02 |
Axikin Pharmaceuticals, Inc. |
Arylsulfonamide CCR3 antagonists
|
EP2749554B1
(en)
|
2009-04-22 |
2017-12-20 |
SMA Therapeutics, Inc. |
2,5-disubstituted arylsulfonamide CCR3 antagonists
|
AR078120A1
(es)
|
2009-04-22 |
2011-10-19 |
Axikin Pharmaceuticals Inc |
Antagonistas de ccr3 de arilsulfonamida 2,5-disustituida y composiciones farmaceuticas
|
US20100292281A1
(en)
*
|
2009-05-15 |
2010-11-18 |
The University Of Kentucky Research Foundation |
Treatment of mci and alzheimer's disease
|
US9968574B2
(en)
*
|
2009-05-15 |
2018-05-15 |
The University Of Kentucky Research Foundation |
Treatment of MCI and Alzheimer's disease
|
BRPI1012196B1
(pt)
|
2009-05-18 |
2021-11-30 |
Sublimity Therapeutics Limited |
Composição compreendendo gotas de óleo
|
WO2010137547A1
(ja)
|
2009-05-25 |
2010-12-02 |
国立大学法人東京工業大学 |
中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物
|
KR20120035183A
(ko)
|
2009-06-10 |
2012-04-13 |
선오비온 파마슈티컬스 인코포레이티드 |
히스타민 h3 역 작용제 및 길항제, 및 이의 사용 방법
|
US9050276B2
(en)
|
2009-06-16 |
2015-06-09 |
The Trustees Of Columbia University In The City Of New York |
Autism-associated biomarkers and uses thereof
|
WO2011003870A2
(en)
|
2009-07-06 |
2011-01-13 |
Creabilis S.A. |
Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
|
EP2451802A1
(en)
|
2009-07-07 |
2012-05-16 |
Pathway Therapeutics, Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
|
CA2767576C
(en)
|
2009-07-08 |
2020-03-10 |
Charleston Laboratories Inc. |
Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
|
CA2767168C
(en)
|
2009-07-08 |
2019-04-09 |
Hope Medical Enterprises, Inc. D.B.A. Hope Pharmaceuticals |
Sodium thiosulfate-containing pharmaceutical compositions
|
EP2467144A1
(en)
|
2009-07-24 |
2012-06-27 |
ViroLogik GmbH |
Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
|
US8404728B2
(en)
|
2009-07-30 |
2013-03-26 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
WO2011014775A1
(en)
|
2009-07-31 |
2011-02-03 |
The Brigham And Women's Hospital, Inc. |
Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
|
AR077712A1
(es)
|
2009-08-05 |
2011-09-14 |
Idenix Pharmaceuticals Inc |
Inhibidores de serina proteasa macrociclica
|
GB2485327A
(en)
|
2009-08-12 |
2012-05-09 |
Sigmoid Pharma Ltd |
Immunomodulatory compositions comprising a polymer matrix and an oil phase
|
JP2013502429A
(ja)
|
2009-08-19 |
2013-01-24 |
アムビト ビオスシエンセス コルポラチオン |
ビアリール化合物及びその使用方法
|
EP2473038A4
(en)
|
2009-09-04 |
2013-10-23 |
United Paragon Associates Inc |
COMPOSITIONS FOR TREATING SUFFICIENT OR ILLNESSES PROVIDED BY NEUROKININ-2-RECEPTOR ACTIVITY
|
EP2475662A2
(en)
|
2009-09-11 |
2012-07-18 |
Sunovion Pharmaceuticals Inc. |
Histamine h3 inverse agonists and antagonists and methods of use thereof
|
US20110136751A1
(en)
|
2009-10-06 |
2011-06-09 |
Green Molecular |
Use of Polyphenols in the Treatment of Cancer
|
RS53716B1
(en)
|
2009-10-19 |
2015-04-30 |
Synta Pharmaceuticals Corp. |
COMBINED CANCER THERAPY WITH HSP90 INHIBITORS
|
WO2011056566A2
(en)
|
2009-10-26 |
2011-05-12 |
Sunesis Pharmaceuticals, Inc. |
Compounds and methods for treatment of cancer
|
EP2325185A1
(en)
|
2009-10-28 |
2011-05-25 |
GPC Biotech AG |
Plk inhibitor
|
WO2011056764A1
(en)
|
2009-11-05 |
2011-05-12 |
Ambit Biosciences Corp. |
Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
|
EP2501382A1
(en)
|
2009-11-19 |
2012-09-26 |
Celgene Corporation |
Apremilast for the treatment of sarcoidosis
|
WO2011063076A1
(en)
|
2009-11-19 |
2011-05-26 |
Itherx Pharmaceuticals, Inc. |
Methods of treating hepatitis c virus with oxoacetamide compounds
|
EP2501234B1
(en)
*
|
2009-11-20 |
2017-09-13 |
Tonix Pharma Holdings Limited |
Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine
|
WO2011064769A1
(en)
|
2009-11-24 |
2011-06-03 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Methods and pharmaceutical compositions for the treatment of hot flashes
|
WO2011069002A1
(en)
|
2009-12-02 |
2011-06-09 |
Alquest Therapeutics, Inc. |
Organoselenium compounds and uses thereof
|
BR112012013325B8
(pt)
|
2009-12-04 |
2021-05-25 |
Sunovion Pharmaceuticals Inc |
composição farmacêutica e uso
|
US8710245B2
(en)
|
2009-12-04 |
2014-04-29 |
Psychogenics Inc. |
Multicyclic compounds and methods of use thereof
|
EP2509615A1
(en)
|
2009-12-09 |
2012-10-17 |
Scynexis, Inc. |
Novel cyclic peptides
|
MY159958A
(en)
|
2009-12-18 |
2017-02-15 |
Idenix Pharmaceuticals Inc |
5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
|
AU2010333767A1
(en)
|
2009-12-22 |
2012-07-05 |
Celgene Corporation |
(Methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses
|
US8710092B2
(en)
*
|
2009-12-23 |
2014-04-29 |
Map Pharmaceuticals, Inc. |
Substituted indolo 4,3 FG quinolines useful for treating migraine
|
CN102834409A
(zh)
|
2009-12-30 |
2012-12-19 |
西尼克斯公司 |
环孢菌素类似物
|
USRE49251E1
(en)
|
2010-01-04 |
2022-10-18 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
PT3536333T
(pt)
|
2010-01-04 |
2022-11-11 |
Mapi Pharma Ltd |
Sistema de depósito compreendendo acetato de glatirâmero
|
MX337566B
(es)
|
2010-01-05 |
2016-03-10 |
Celgene Corp |
Combinación de un compuesto inmunomodulador y una artemisinina o un derivado de ésta para tratar cáncer.
|
WO2011089167A1
(en)
|
2010-01-19 |
2011-07-28 |
Virologik Gmbh |
Kombination of proteasome inhibitors and anti -hepatitis medication for treating retroviral diseases
|
WO2011094890A1
(en)
|
2010-02-02 |
2011-08-11 |
Argusina Inc. |
Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
|
UA115523C2
(uk)
|
2010-02-05 |
2017-11-27 |
Общєство С Огранічєнной Отвєтствєнностью "Новамєдіка" |
Тверді форми макроциклічних інгібіторів кінази
|
RS58523B1
(sr)
|
2010-02-11 |
2019-04-30 |
Celgene Corp |
Derivati arilmetoksi izoindolina i kombinacije koje ih obuhvataju i postupci njihove upotrebe
|
DK2542542T3
(en)
|
2010-03-02 |
2015-07-20 |
Axikin Pharmaceuticals Inc |
ISOTOPIC ENRICHED ARYL SULPHONAMIDE CCR3 ANTAGONISTS
|
WO2011112689A2
(en)
|
2010-03-11 |
2011-09-15 |
Ambit Biosciences Corp. |
Saltz of an indazolylpyrrolotriazine
|
AU2011224166B2
(en)
*
|
2010-03-12 |
2014-08-21 |
Celgene Corporation |
Methods for the treatment of non-Hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor
|
WO2011116161A2
(en)
|
2010-03-17 |
2011-09-22 |
Axikin Pharmaceuticals Inc. |
Arylsulfonamide ccr3 antagonists
|
JP2013522321A
(ja)
|
2010-03-19 |
2013-06-13 |
パーデュー・リサーチ・ファウンデーション |
Hivを治療するためのccr5モジュレーター
|
CA2794096A1
(en)
|
2010-04-07 |
2011-10-13 |
Celgene Corporation |
Methods for treating respiratory viral infection
|
EP2556082B1
(en)
|
2010-04-08 |
2017-02-22 |
Emory University |
Substituted androst-4-ene diones
|
EP2560640A1
(en)
|
2010-04-19 |
2013-02-27 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
|
WO2011133521A2
(en)
|
2010-04-19 |
2011-10-27 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
|
WO2011137249A1
(en)
|
2010-04-28 |
2011-11-03 |
Ritter Pharmaceuticals, Inc. |
Prebiotic formulations and methods of use
|
WO2011140360A1
(en)
|
2010-05-05 |
2011-11-10 |
The Trustees Of Columbia University In The City Of New York |
Radiolabeled compounds and uses thereof
|
WO2011146803A1
(en)
|
2010-05-20 |
2011-11-24 |
Synta Pharmaceuticals Corp. |
Method of treating lung adenocarcinoma with hsp90 inhibitory compounds
|
EP2575810A1
(en)
|
2010-05-24 |
2013-04-10 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
|
US8969349B2
(en)
|
2010-05-26 |
2015-03-03 |
Sunovion Pharmaceuticals Inc. |
Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors
|
US9296722B2
(en)
|
2010-05-27 |
2016-03-29 |
Ambit Biosciences Corporation |
Azolyl urea compounds and methods of use thereof
|
WO2011150201A2
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl amide compounds and methods of use thereof
|
JP2013528180A
(ja)
|
2010-05-28 |
2013-07-08 |
ジーイー・ヘルスケア・リミテッド |
放射性標識化合物及びその製造方法
|
AU2011261501B2
(en)
|
2010-06-01 |
2016-01-21 |
Biotheryx, Inc. |
Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone
|
JP5844354B2
(ja)
|
2010-06-01 |
2016-01-13 |
ビオトヘルイク, インコーポレイテッド |
ヒドロキシピリドン誘導体、その医薬組成物、及び増殖性疾患治療のためのその治療的使用
|
MX367469B
(es)
|
2010-06-07 |
2019-08-23 |
Novomedix Llc |
Compuestos furanilo y su uso.
|
US20110319389A1
(en)
|
2010-06-24 |
2011-12-29 |
Tonix Pharmaceuticals, Inc. |
Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
|
US20130178522A1
(en)
|
2010-07-19 |
2013-07-11 |
James M. Jamison |
Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
|
JP5820476B2
(ja)
|
2010-08-24 |
2015-11-24 |
アルギアックス ファルマコウティカルス ゲーエムベーハーALGIAX Pharmaceuticals GmbH |
レフルノミドおよびマロノニトリラマイドの新規の使用
|
WO2012030924A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Azolopyridine and azolopyrimidine compounds and methods of use thereof
|
EP2611793A1
(en)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
2-cycloquinazoline derivatives and methods of use thereof
|
WO2012030918A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Adenosine a3 receptor modulating compounds and methods of use thereof
|
CN103298805A
(zh)
|
2010-09-01 |
2013-09-11 |
埃姆比特生物科学公司 |
喹唑啉化合物及其使用方法
|
CN103270030B
(zh)
|
2010-09-01 |
2016-01-20 |
埃姆比特生物科学公司 |
吡唑基氨基喹唑啉的氢溴酸盐
|
US20130296363A1
(en)
|
2010-09-01 |
2013-11-07 |
Ambit Biosciences Corporation |
Quinoline and isoquinoline derivatives for use as jak modulators
|
JP5933554B2
(ja)
|
2010-09-01 |
2016-06-15 |
アムビト ビオスシエンセス コルポラチオン |
光学活性のあるピラゾリルアミノキナゾリン及びその医薬組成物及び使用方法
|
US20130225578A1
(en)
|
2010-09-01 |
2013-08-29 |
Ambit Biosciences Corporation |
7-cyclylquinazoline derivatives and methods of use thereof
|
EP2611794A1
(en)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
4-azolylaminoquinazoline derivatives and methods of use thereof
|
US20130317045A1
(en)
|
2010-09-01 |
2013-11-28 |
Ambit Biosciences Corporation |
Thienopyridine and thienopyrimidine compounds and methods of use thereof
|
EP2616063A1
(en)
|
2010-09-13 |
2013-07-24 |
Synta Pharmaceuticals Corp. |
Hsp90 inhibitors for treating non-small cell lung cancers in wild-type egfr and/or kras patients
|
WO2012044641A1
(en)
|
2010-09-29 |
2012-04-05 |
Pathway Therapeutics Inc. |
1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
AU2011313906B2
(en)
|
2010-10-11 |
2015-08-13 |
Axikin Pharmaceuticals, Inc. |
Salts of arylsulfonamide CCR3 antagonists
|
ES2564358T3
(es)
|
2010-10-15 |
2016-03-22 |
The Trustees Of Columbia University In The City Of New York |
Genes relacionados con la obesidad y sus proteínas y usos de los mismos
|
PT2629776T
(pt)
|
2010-10-18 |
2017-11-15 |
Cerenis Therapeutics Holding Sa |
Compostos, composições e métodos úteis para a mobilização de colesterol
|
HUE034890T2
(hu)
|
2010-10-29 |
2018-03-28 |
Algiax Pharmaceuticals Gmbh |
Malononitrilaminok alkalmazása neuropathiás fájdalomban
|
US20130289071A1
(en)
|
2010-11-09 |
2013-10-31 |
Synta Pharmaceuticals Corp. |
Tetrazolyl-tetrahydropyridine compounds for inflammation and immune-related uses
|
WO2012064973A2
(en)
|
2010-11-10 |
2012-05-18 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
GB201020032D0
(en)
|
2010-11-25 |
2011-01-12 |
Sigmoid Pharma Ltd |
Composition
|
CA2819859A1
(en)
|
2010-12-06 |
2012-06-14 |
Follica, Inc. |
Methods for treating baldness and promoting hair growth
|
WO2012078492A1
(en)
|
2010-12-06 |
2012-06-14 |
Celgene Corporation |
A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
|
WO2012078757A2
(en)
|
2010-12-08 |
2012-06-14 |
Synta Pharmaceuticals Corp. |
Combination breast cancer therapy with hsp90 inhibitory compounds
|
WO2012080050A1
(en)
|
2010-12-14 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Solid forms of a phenoxybenzenesulfonyl compound
|
US9532977B2
(en)
|
2010-12-16 |
2017-01-03 |
Celgene Corporation |
Controlled release oral dosage forms of poorly soluble drugs and uses thereof
|
WO2012083017A2
(en)
|
2010-12-16 |
2012-06-21 |
Celgene Corporation |
Controlled release oral dosage forms of poorly soluble drugs and uses thereof
|
AU2011346749A1
(en)
|
2010-12-22 |
2013-05-02 |
Purdue Pharma L.P. |
Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof
|
BR112013017411B1
(pt)
|
2011-01-07 |
2022-03-22 |
Anji Pharma (Us) Llc |
Uso de uma composição compreendendo metformina ou um sal da mesma
|
WO2012096859A2
(en)
|
2011-01-10 |
2012-07-19 |
Celgene Corporation |
Oral dosage forms of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl]-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amide
|
CN103648499B
(zh)
|
2011-01-10 |
2017-02-15 |
无限药品股份有限公司 |
用于制备异喹啉酮的方法及异喹啉酮的固体形式
|
US8853175B2
(en)
|
2011-01-10 |
2014-10-07 |
Celgene Corporation |
Phenethylsulfone isoindoline derivatives and their use
|
EP2663305A1
(en)
|
2011-01-11 |
2013-11-20 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors
|
JP6106603B2
(ja)
|
2011-01-11 |
2017-04-05 |
スノビオン プハルマセウトイカルス インコーポレイテッド |
ヘテロアリール化合物及びその使用方法
|
US9045417B2
(en)
|
2011-01-14 |
2015-06-02 |
Celgene Corporation |
Isotopologues of isoindole derivatives
|
US9566269B2
(en)
|
2011-01-20 |
2017-02-14 |
Bionevia Pharmaceuticals Inc. |
Modified release compositions of epalrestat or a derivative thereof and methods for using the same
|
WO2012106281A2
(en)
|
2011-01-31 |
2012-08-09 |
The General Hospital Corporation |
Multimodal trail molecules and uses in cellular therapies
|
EP2670396A1
(en)
|
2011-01-31 |
2013-12-11 |
Celgene Corporation |
Pharmaceutical compositions of cytidine analogs and methods of use thereof
|
WO2012109398A1
(en)
|
2011-02-10 |
2012-08-16 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
|
US20140051664A1
(en)
|
2011-02-23 |
2014-02-20 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitory compounds with radiotherapy
|
US20140051665A1
(en)
|
2011-02-24 |
2014-02-20 |
Synta Pharmaceuticals Corp. |
Prostate cancer therapy with hsp90 inhibitory compounds
|
US20140045908A1
(en)
|
2011-02-25 |
2014-02-13 |
Synta Pharmaceuticals Corp. |
Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers
|
US9795792B2
(en)
|
2011-02-25 |
2017-10-24 |
Medtronic, Inc. |
Emergency mode switching for non-pacing modes
|
US9387195B2
(en)
|
2011-03-07 |
2016-07-12 |
Celgene Corporation |
Methods for treating diseases using isoindoline compounds
|
US20120232159A1
(en)
|
2011-03-07 |
2012-09-13 |
Tonix Pharmaceuticals, Inc. |
Methods and Compositions for Treating Depression using Cyclobenzaprine
|
CA2829592A1
(en)
|
2011-03-11 |
2012-09-20 |
Celgene Corporation |
Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione
|
MX2013010360A
(es)
|
2011-03-11 |
2014-04-14 |
Celgene Corp |
Formas solidas sde 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-pi peridin-2,6-diona, y sus composiciones farmaceuticas y usos.
|
US20140038967A1
(en)
|
2011-03-17 |
2014-02-06 |
Algiax Pharmaceuticals Gmbh |
Novel use for imidazotriazinones
|
EP2685975A1
(en)
|
2011-03-17 |
2014-01-22 |
Algiax Pharmaceuticals GmbH |
Novel use of benzofuranylsulfonates
|
CA2830069C
(en)
|
2011-03-20 |
2019-11-12 |
The University Of British Columbia |
Therapeutic agent for emphysema and copd
|
EP2699091B1
(en)
|
2011-03-28 |
2017-06-21 |
DeuteRx, LLC |
2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
|
AU2012236722A1
(en)
|
2011-03-28 |
2013-10-17 |
Mei Pharma, Inc. |
(alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
US20140088103A1
(en)
|
2011-03-28 |
2014-03-27 |
Mei Pharma, Inc. |
(fused ring arylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
WO2012135160A1
(en)
|
2011-03-28 |
2012-10-04 |
Pathway Therapeutics Inc. |
(alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
EP2691409B1
(en)
|
2011-03-31 |
2018-02-21 |
Idenix Pharmaceuticals LLC. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
US20120321590A1
(en)
|
2011-04-06 |
2012-12-20 |
Anadys Pharmaceuticals, Inc. |
Bridged polycyclic compounds
|
AU2012245287B2
(en)
|
2011-04-21 |
2017-04-13 |
Curemark, Llc |
Compounds for the treatment of neuropsychiatric disorders
|
WO2012143924A1
(en)
|
2011-04-21 |
2012-10-26 |
Mapi Pharma Ltd. |
Random pentapolymer for treatment of autoimmune diseases
|
JP6022548B2
(ja)
|
2011-04-28 |
2016-11-09 |
セルジーン コーポレイション |
Pde4阻害剤を自己免疫疾患及び炎症性疾患の治療及び管理に使用する方法及び組成物
|
AU2012249491B2
(en)
|
2011-04-29 |
2016-12-15 |
Celgene Corporation |
Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
|
CA2834928C
(en)
|
2011-05-03 |
2017-10-17 |
Synta Pharmaceuticals Corp. |
Compounds for inflammation and immune-related uses
|
EP2704726B1
(en)
|
2011-05-04 |
2018-10-31 |
Trustees of Boston University |
Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria
|
US20140315943A1
(en)
|
2011-05-24 |
2014-10-23 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitory compounds with mtor/p13k inhibitors
|
AU2012262489A1
(en)
|
2011-05-27 |
2013-04-04 |
Icahn School Of Medicine At Mount Sinai |
Substituted 2-benzylidene-2H-benzo[b][1,4]thiazin-3(4H)-ones, derivatives thereof, and therapeutic uses thereof
|
SG195288A1
(en)
|
2011-06-07 |
2013-12-30 |
Anadys Pharmaceuticals Inc |
[1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid
|
RU2011122942A
(ru)
|
2011-06-08 |
2012-12-20 |
Общество С Ограниченной Ответственностью "Асинэкс Медхим" |
Новые ингибиторы киназ
|
US20140221427A1
(en)
|
2011-06-22 |
2014-08-07 |
Celgene Corporation |
Isotopologues of pomalidomide
|
UA113288C2
(xx)
|
2011-06-22 |
2017-01-10 |
|
Trpv1 антагоністи, що містять дигідроксизамісник, і їх застосування
|
BR112013033339A2
(pt)
|
2011-06-23 |
2016-08-16 |
Map Pharmaceuticals Inc |
análogos de fluorergolina
|
US20140227293A1
(en)
|
2011-06-30 |
2014-08-14 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
EP2729144A2
(en)
|
2011-07-07 |
2014-05-14 |
Synta Pharmaceuticals Corp. |
Treating cancer with hsp90 inhibitory compounds
|
EP2734520B1
(en)
|
2011-07-19 |
2016-09-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
CA2842190A1
(en)
|
2011-07-19 |
2013-01-24 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
GB201112987D0
(en)
|
2011-07-28 |
2011-09-14 |
Ge Healthcare Ltd |
Novel compound
|
WO2013022872A1
(en)
|
2011-08-10 |
2013-02-14 |
Celgene Corporation |
Gene methylation biomarkers and methods of use thereof
|
WO2013021276A1
(en)
|
2011-08-10 |
2013-02-14 |
Purdue Pharma L.P. |
Trpv1 antagonists including dihydroxy substituent and uses thereof
|
CN103930126A
(zh)
|
2011-08-12 |
2014-07-16 |
Bsrc亚历山大.弗莱明 |
Tnf超家族三聚化的抑制剂
|
WO2013028505A1
(en)
|
2011-08-19 |
2013-02-28 |
Synta Pharmaceuticals Corp. |
Combination cancer therapy of hsp90 inhibitor with antimetabolite
|
ES2624710T3
(es)
|
2011-08-23 |
2017-07-17 |
Cornerstone Therapeutics Inc. |
Uso de zileutón en el tratamiento de pólipos nasales en pacientes con fibrosis quística
|
WO2013032591A1
(en)
|
2011-08-29 |
2013-03-07 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
EP2755983B1
(en)
|
2011-09-12 |
2017-03-15 |
Idenix Pharmaceuticals LLC. |
Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
|
US8951985B2
(en)
|
2011-09-12 |
2015-02-10 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
US20130071394A1
(en)
|
2011-09-16 |
2013-03-21 |
John K. Troyer |
Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
|
CA2849708A1
(en)
|
2011-09-23 |
2013-03-28 |
Celgene Corporation |
Romidepsin and 5 - azacitidine for use in treating lymphoma
|
AU2012316266B2
(en)
|
2011-09-26 |
2015-07-30 |
Celgene Corporation |
Combination therapy for chemoresistant cancers
|
US9630979B2
(en)
|
2011-09-29 |
2017-04-25 |
Infinity Pharmaceuticals, Inc. |
Inhibitors of monoacylglycerol lipase and methods of their use
|
US9610370B2
(en)
|
2011-10-07 |
2017-04-04 |
University Of Virginia Patent Foundation |
Compositions and methods for tumor imaging and targeting by a class of organic heptamethine cyanine dyes that possess dual nuclear and near-infrared properties
|
EP2766041B1
(en)
|
2011-10-12 |
2018-12-05 |
Children's Medical Center Corporation |
Combinatorial compositions and methods of treating hemoglobinopathies
|
KR102066297B1
(ko)
|
2011-10-14 |
2020-01-14 |
암비트 바이오사이언시즈 코포레이션 |
헤테로사이클릭 화합물 및 이의 유형 3 수용체 티로신 키나아제의 조절인자로서의 용도
|
US8507460B2
(en)
|
2011-10-14 |
2013-08-13 |
Idenix Pharmaceuticals, Inc. |
Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
|
TWI558401B
(zh)
|
2011-11-01 |
2016-11-21 |
西建公司 |
利用胞嘧啶核苷類似物之口服配方治療癌症的方法
|
CA2853806C
(en)
|
2011-11-02 |
2020-07-14 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitors with platinum-containing agents
|
CA2853799A1
(en)
|
2011-11-02 |
2013-05-10 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
|
WO2013071049A1
(en)
|
2011-11-10 |
2013-05-16 |
Trustees Of Boston College |
Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity
|
US9402831B2
(en)
|
2011-11-14 |
2016-08-02 |
Synta Pharmaceutical Corp. |
Combination therapy of HSP90 inhibitors with BRAF inhibitors
|
ES2583146T3
(es)
|
2011-12-01 |
2016-09-19 |
Purdue Pharma L.P. |
Compuestos de piperidina de tipo quinoxalina sustituidos con azetidina y usos de éstos
|
US20130143867A1
(en)
|
2011-12-02 |
2013-06-06 |
Sychroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
WO2013085902A1
(en)
|
2011-12-05 |
2013-06-13 |
The University Of Texas M.D. |
Combination therapy methods for treating an inflammatory breast cancer
|
AU2012324012A1
(en)
|
2011-12-08 |
2013-06-27 |
Purdue Pharma L.P. |
Quaternized buprenorphine analogs
|
SG11201403434YA
(en)
|
2011-12-19 |
2014-09-26 |
Map Pharmaceuticals Inc |
Novel iso-ergoline derivatives
|
EP2793583A4
(en)
|
2011-12-21 |
2015-08-12 |
Map Pharmaceuticals Inc |
NOVEL NEUROMODULATORY CONNECTIONS
|
WO2013102144A2
(en)
|
2011-12-30 |
2013-07-04 |
Halozyme, Inc. |
Ph20 polypeptede variants, formulations and uses thereof
|
CN104271197A
(zh)
|
2012-01-05 |
2015-01-07 |
波士顿医疗中心有限公司 |
用于诊断和治疗肾脏疾病的slit-robo信号
|
EA033067B1
(ru)
|
2012-01-06 |
2019-08-30 |
Элселикс Терапьютикс, Инк. |
Способ лечения метаболических расстройств у пациента, имеющего противопоказание к назначению бигуанидного соединения
|
AU2012363873B2
(en)
|
2012-01-06 |
2017-11-23 |
Anji Pharmaceuticals Inc. |
Biguanide compositions and methods of treating metabolic disorders
|
EP2812324B1
(en)
|
2012-02-08 |
2021-09-01 |
Sunovion Pharmaceuticals Inc. |
Heteroaryl compounds and methods of use thereof
|
ES2671608T3
(es)
|
2012-02-21 |
2018-06-07 |
Celgene Corporation |
Formas sólidas de 3-(4-nitro-1-oxoisoindolin-2-il)piperidina-2,6-diona
|
WO2013130422A1
(en)
|
2012-02-27 |
2013-09-06 |
Biovista, Inc. |
Compositions and methods for treating mitochondrial diseases
|
US9611253B2
(en)
|
2012-02-29 |
2017-04-04 |
Ambit Biosciences Corporation |
Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
|
WO2013133708A1
(en)
|
2012-03-07 |
2013-09-12 |
Stichting Vu-Vumc |
Compositions and methods for diagnosing and treating intellectual disability syndrome, autism and autism related disorders
|
US9365556B2
(en)
|
2012-03-16 |
2016-06-14 |
Axikin Pharmaceuticals, Inc. |
3,5-diaminopyrazole kinase inhibitors
|
CA2901394A1
(en)
|
2012-03-19 |
2013-09-26 |
The Brigham And Women's Hosptial, Inc. |
Growth differentiation factor (gdf) for treatment of diastolic heart failure
|
US10039777B2
(en)
|
2012-03-20 |
2018-08-07 |
Neuro-Lm Sas |
Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
|
US20140350087A9
(en)
|
2012-03-22 |
2014-11-27 |
Halozyme, Inc. |
Oncovector Nucleic Acid Molecules and Methods of Use
|
CN104302286A
(zh)
|
2012-03-27 |
2015-01-21 |
英丘伦有限责任公司 |
用于治疗乳腺癌的curaxin和用于鉴别可能响应的患者的方法
|
CA2868258A1
(en)
|
2012-03-28 |
2013-10-03 |
Synta Pharmaceuticals Corp. |
Triazole derivatives as hsp90 inhibitors
|
CA2868323A1
(en)
|
2012-04-04 |
2013-10-10 |
Synta Pharmaceuticals Corp. |
Novel triazole compounds that modulate hsp90 activity
|
CA2869460C
(en)
|
2012-04-04 |
2018-05-15 |
Halozyme, Inc. |
Combination therapy with an anti-hyaluronan agent and a tumor-targeted taxane
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2013156231A1
(en)
|
2012-04-16 |
2013-10-24 |
Algiax Pharmaceuticals Gmbh |
Use of imidazotriazinones in neuropathic pain
|
WO2013156232A1
(en)
|
2012-04-16 |
2013-10-24 |
Algiax Pharmaceuticals Gmbh |
Use of benzofuranylsulfonates in neuropathic pain
|
JP6279547B2
(ja)
|
2012-04-17 |
2018-02-14 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
オピオイド誘発性有害薬力学的応答を治療するためのシステムおよび方法
|
WO2013158928A2
(en)
|
2012-04-18 |
2013-10-24 |
Elcelyx Therapeutics, Inc. |
Chemosensory receptor ligand-based therapies
|
WO2013163758A1
(en)
|
2012-05-01 |
2013-11-07 |
Boyd Shelley Romayne |
Methods for treating and diagnosing blinding eye diseases
|
CA2871540A1
(en)
|
2012-05-10 |
2013-11-14 |
Synta Pharmaceuticals Corp. |
Treating cancer with hsp90 inhibitory compounds
|
US20150210646A1
(en)
|
2012-05-11 |
2015-07-30 |
Purdue Pharma L.P. |
Benzomorphan compounds as opioid receptors modulators
|
GB201208315D0
(en)
|
2012-05-11 |
2012-06-27 |
Numedicus Ltd |
Pharmaceutical methods and compositions
|
EP2852604B1
(en)
|
2012-05-22 |
2017-04-12 |
Idenix Pharmaceuticals LLC |
3',5'-cyclic phosphoramidate prodrugs for hcv infection
|
AU2013266393B2
(en)
|
2012-05-22 |
2017-09-28 |
Idenix Pharmaceuticals Llc |
D-amino acid compounds for liver disease
|
US9296778B2
(en)
|
2012-05-22 |
2016-03-29 |
Idenix Pharmaceuticals, Inc. |
3′,5′-cyclic phosphate prodrugs for HCV infection
|
US10350278B2
(en)
|
2012-05-30 |
2019-07-16 |
Curemark, Llc |
Methods of treating Celiac disease
|
WO2013187965A1
(en)
|
2012-06-14 |
2013-12-19 |
Mayo Foundation For Medical Education And Research |
Pyrazole derivatives as inhibitors of stat3
|
BR112014031421A2
(pt)
|
2012-06-15 |
2017-06-27 |
Brigham & Womens Hospital Inc |
composições para tratamento de câncer e métodos para produção das mesmas
|
US9012640B2
(en)
|
2012-06-22 |
2015-04-21 |
Map Pharmaceuticals, Inc. |
Cabergoline derivatives
|
WO2014004990A2
(en)
|
2012-06-29 |
2014-01-03 |
Celgene Corporation |
Methods for determining drug efficacy using cereblon-associated proteins
|
GB201212010D0
(en)
|
2012-07-05 |
2012-08-22 |
Sigmoid Pharma Ltd |
Formulations
|
CN104780915A
(zh)
|
2012-07-11 |
2015-07-15 |
埃尔舍利克斯治疗公司 |
包含他汀、双胍和用于减小心脏代谢风险的其它药剂的组合物
|
US9034870B2
(en)
|
2012-07-13 |
2015-05-19 |
Purdue Research Foundation |
Azaindenoisoquinoline topoisomerase I inhibitors
|
US9085561B2
(en)
|
2012-07-30 |
2015-07-21 |
Purdue Pharma L.P. |
Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators
|
CA2916638C
(en)
|
2012-07-31 |
2021-01-12 |
The Brigham And Women's Hospital, Inc. |
Modulation of the immune response
|
LT2882441T
(lt)
|
2012-08-09 |
2020-07-27 |
Celgene Corporation |
Su imunitetu susijusių ir uždegiminių ligų gydymas
|
CN108245518B
(zh)
|
2012-08-09 |
2021-08-31 |
细胞基因公司 |
利用3-(4-((4-(吗啉代甲基)苯甲基)氧基)-1-氧代异二氢吲哚-2-基)哌啶-2,6- 二酮治疗癌症的方法
|
CA2878954C
(en)
|
2012-08-09 |
2020-12-08 |
Benjamin M. Cohen |
Salts and solid forms of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same
|
US9587281B2
(en)
|
2012-08-14 |
2017-03-07 |
Celgene Corporation |
Cereblon isoforms and their use as biomarkers for therapeutic treatment
|
WO2014030053A1
(en)
|
2012-08-20 |
2014-02-27 |
Rhodes Technologies |
Systems and methods for increasing stability of dronabinol compositions
|
US9315514B2
(en)
|
2012-08-27 |
2016-04-19 |
Rhodes Technologies |
1,3-dioxanomorphides and 1,3-dioxanocodides
|
EP2890720B1
(en)
|
2012-08-30 |
2019-07-17 |
The General Hospital Corporation |
Compositions and methods for treating cancer
|
US9750705B2
(en)
|
2012-08-31 |
2017-09-05 |
The Regents Of The University Of California |
Agents useful for treating obesity, diabetes and related disorders
|
EP2892884A1
(en)
|
2012-09-07 |
2015-07-15 |
Axikin Pharmaceuticals, Inc. |
Isotopically enriched arylsulfonamide ccr3 antagonists
|
KR20150054962A
(ko)
|
2012-09-10 |
2015-05-20 |
셀진 코포레이션 |
국소 진행성 유방암의 치료방법
|
WO2014055647A1
(en)
|
2012-10-03 |
2014-04-10 |
Mei Pharma, Inc. |
(sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
|
ES2674980T3
(es)
|
2012-10-08 |
2018-07-05 |
Idenix Pharmaceuticals Llc |
Análogos de 2'-cloro nucleósidos para infección por VHC
|
JP6356134B2
(ja)
|
2012-10-12 |
2018-07-11 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. |
免疫応答の増強
|
US9278124B2
(en)
|
2012-10-16 |
2016-03-08 |
Halozyme, Inc. |
Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
|
EP2909223B1
(en)
|
2012-10-19 |
2017-03-22 |
Idenix Pharmaceuticals LLC |
Dinucleotide compounds for hcv infection
|
US10723754B2
(en)
|
2012-10-22 |
2020-07-28 |
Idenix Pharmaceuticals Llc |
2′,4′-bridged nucleosides for HCV infection
|
ES2691742T5
(es)
|
2012-11-01 |
2022-03-18 |
Infinity Pharmaceuticals Inc |
Tratamiento de cánceres utilizando moduladores de isoformas de PI3 cinasa
|
US20150272924A1
(en)
|
2012-11-08 |
2015-10-01 |
Summa Health System |
Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
|
JP6400592B2
(ja)
|
2012-11-09 |
2018-10-03 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
ベンゾモルファン類似体およびその使用
|
JP2015536991A
(ja)
|
2012-11-09 |
2015-12-24 |
セルジーン コーポレイション |
骨量の減少の治療方法
|
US20140140951A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-Alanine Ester of Rp-Nucleoside Analog
|
WO2014078436A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-alanine ester of sp-nucleoside analog
|
US9670230B2
(en)
|
2012-11-29 |
2017-06-06 |
Sunovion Pharmaceuticals Inc. |
Heteroaryl compounds and methods of use thereof
|
JP6313779B2
(ja)
|
2012-11-30 |
2018-04-18 |
ノボメディックス, エルエルシーNovomedix, Llc |
置換ビアリールスルホンアミドおよびその利用
|
TW201434842A
(zh)
|
2012-12-07 |
2014-09-16 |
Purdue Pharma Lp |
丁基原啡因(buprenorphine)類似物類
|
EP2931724B1
(en)
|
2012-12-14 |
2017-01-25 |
Purdue Pharma LP |
Pyridonemorphinan analogs and biological activity on opioid receptors
|
CA2894971C
(en)
|
2012-12-14 |
2018-06-26 |
Purdue Pharma L.P. |
Nitrogen containing morphinan derivatives and the use thereof
|
JP6141444B2
(ja)
|
2012-12-14 |
2017-06-07 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
スピロ環式モルフィナンおよびこれらの使用
|
EP2935304A1
(en)
|
2012-12-19 |
2015-10-28 |
IDENIX Pharmaceuticals, Inc. |
4'-fluoro nucleosides for the treatment of hcv
|
JP2016503795A
(ja)
|
2012-12-21 |
2016-02-08 |
マップ ファーマシューティカルズ インコーポレイテッド |
新規メチセルジド誘導体
|
US9090618B2
(en)
|
2012-12-27 |
2015-07-28 |
Purdue Pharma L.P. |
Substituted benzimidazole-type piperidine compounds and uses thereof
|
WO2014102588A2
(en)
|
2012-12-27 |
2014-07-03 |
Purdue Pharma L.P. |
Indole and indoline-type piperidine compounds and uses thereof
|
WO2014102592A2
(en)
|
2012-12-27 |
2014-07-03 |
Purdue Pharma L.P. |
Oxime/substituted quinoxaline-type piperidine compounds and uses thereof
|
WO2014102589A1
(en)
|
2012-12-27 |
2014-07-03 |
Purdue Pharma L.P. |
Quinazolin-4(3h)-one-type piperidine compounds and uses thereof
|
US10118927B2
(en)
|
2012-12-27 |
2018-11-06 |
Purdue Pharma L.P. |
Substituted piperidin-4-amino-type compounds and uses thereof
|
EP2941431B1
(en)
|
2012-12-28 |
2017-10-25 |
Purdue Pharma L.P. |
Substituted morphinans and the use thereof
|
JP6159416B2
(ja)
|
2012-12-28 |
2017-07-05 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
7,8−環式モルフィナン類似体
|
US9884844B2
(en)
|
2012-12-31 |
2018-02-06 |
Sunovion Pharmaceuticals, Inc. |
Heterocyclic compounds and methods of use thereof
|
JP6333855B2
(ja)
|
2013-01-05 |
2018-05-30 |
エルセリクス セラピューティクス インコーポレイテッド |
ビグアナイドを含む遅延放出組成物
|
WO2014107745A1
(en)
|
2013-01-07 |
2014-07-10 |
Halozyme, Inc. |
Metal sensitive mutants of matrix metalloproteases and uses thereof
|
WO2014110127A1
(en)
|
2013-01-08 |
2014-07-17 |
Enzo Biochem, Inc. |
Diagnosis and treatment of viral diseases
|
US9617607B2
(en)
|
2013-01-08 |
2017-04-11 |
Enzo Biochem, Inc. |
Diagnosis and treatment of viral diseases
|
NZ630746A
(en)
|
2013-01-11 |
2017-02-24 |
Summa Health System |
Vitamins c and k for treating polycystic diseases
|
US9540340B2
(en)
|
2013-01-14 |
2017-01-10 |
Deuterx, Llc |
3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
|
US9695145B2
(en)
|
2013-01-22 |
2017-07-04 |
Celgene Corporation |
Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
|
US20150342946A1
(en)
|
2013-01-30 |
2015-12-03 |
Pharmorx Therapeutics, Inc. |
Treatments For Depression And Other Diseases With A Low Dose Agent
|
JP6182620B2
(ja)
|
2013-01-31 |
2017-08-16 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
ベンゾモルファン類似体およびその使用
|
WO2014130922A1
(en)
|
2013-02-25 |
2014-08-28 |
Trustees Of Boston University |
Compositions and methods for treating fungal infections
|
US9339541B2
(en)
|
2013-03-04 |
2016-05-17 |
Merck Sharp & Dohme Corp. |
Thiophosphate nucleosides for the treatment of HCV
|
US9309275B2
(en)
|
2013-03-04 |
2016-04-12 |
Idenix Pharmaceuticals Llc |
3′-deoxy nucleosides for the treatment of HCV
|
CN105050624A
(zh)
|
2013-03-14 |
2015-11-11 |
细胞基因公司 |
利用阿普斯特来治疗银屑病关节炎的方法
|
CN108619161A
(zh)
|
2013-03-15 |
2018-10-09 |
加利福尼亚大学董事会 |
无环核苷膦酸二酯
|
NZ629037A
(en)
|
2013-03-15 |
2017-04-28 |
Infinity Pharmaceuticals Inc |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
US10117936B2
(en)
|
2013-03-15 |
2018-11-06 |
Tonix Pharma Holdings Limited |
Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
|
US8969358B2
(en)
|
2013-03-15 |
2015-03-03 |
Purdue Pharma L.P. |
Buprenorphine analogs
|
WO2014165542A1
(en)
|
2013-04-01 |
2014-10-09 |
Idenix Pharmaceuticals, Inc. |
2',4'-fluoro nucleosides for the treatment of hcv
|
JP6469077B2
(ja)
|
2013-04-02 |
2019-02-13 |
セルジーン コーポレイション |
4−アミノ−2−(2,6−ジオキソ−ピペリジン3−イル)−イソインドリン−1,3−ジオンを使用する中枢神経の癌の治療及び管理のための方法及び組成物
|
EP4140497A1
(en)
|
2013-04-08 |
2023-03-01 |
President and Fellows of Harvard College |
Compositions for rejuvenating skeletal muscle stem cells
|
US20160113932A1
(en)
|
2013-05-30 |
2016-04-28 |
Infinity Pharmaceuticals, Inc. |
Treatment of cancers using pi3 kinase isoform modulators
|
EP3878445A3
(en)
|
2013-06-05 |
2021-10-27 |
Synchroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
US10005779B2
(en)
|
2013-06-05 |
2018-06-26 |
Idenix Pharmaceuticals Llc |
1′,4′-thio nucleosides for the treatment of HCV
|
EP3004396B1
(en)
|
2013-06-06 |
2019-10-16 |
The General Hospital Corporation |
Compositions for the treatment of cancer
|
US20160220640A1
(en)
|
2013-06-11 |
2016-08-04 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions for increasing neurogenesis and angiogenesis
|
RU2679896C2
(ru)
|
2013-06-14 |
2019-02-14 |
Акамара Терапьютикс, Инк. |
Соединения на основе платины и липидов и наночастицы
|
EP2815749A1
(en)
|
2013-06-20 |
2014-12-24 |
IP Gesellschaft für Management mbH |
Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
|
WO2014210596A1
(en)
|
2013-06-28 |
2014-12-31 |
Purdue Pharma L.P. |
Treating an arrhythmia with an opioid antagonist
|
TW201534726A
(zh)
|
2013-07-03 |
2015-09-16 |
Halozyme Inc |
熱穩定ph20玻尿酸酶變異體及其用途
|
EP3027636B1
(en)
|
2013-08-01 |
2022-01-05 |
Idenix Pharmaceuticals LLC |
D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
|
EP3036226B1
(en)
|
2013-08-22 |
2020-01-08 |
The General Hospital Corporation |
Inhibitors of human 12/15-lipoxygenase
|
WO2015031765A2
(en)
|
2013-08-29 |
2015-03-05 |
Trustees Of Boston University |
Intermediate metabolism products to potentiate aminoglycoside antibiotics in bacterial infections
|
SG11201601341QA
(en)
|
2013-08-30 |
2016-03-30 |
Ambit Biosciences Corp |
Biaryl acetamide compounds and methods of use thereof
|
NZ631142A
(en)
|
2013-09-18 |
2016-03-31 |
Axikin Pharmaceuticals Inc |
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
|
US20160229866A1
(en)
|
2013-09-20 |
2016-08-11 |
Idenix Pharmaceuticals Inc. |
Hepatitis c virus inhibitors
|
WO2015044759A1
(en)
|
2013-09-24 |
2015-04-02 |
Purdue Pharma L.P. |
Treatment of burn pain by trpv1 modulators
|
US9700549B2
(en)
|
2013-10-03 |
2017-07-11 |
David Wise |
Compositions and methods for treating pelvic pain and other conditions
|
WO2015051241A1
(en)
|
2013-10-04 |
2015-04-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
CA2925944C
(en)
|
2013-10-04 |
2023-01-10 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2015061204A1
(en)
|
2013-10-21 |
2015-04-30 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
CN105899679A
(zh)
|
2013-10-21 |
2016-08-24 |
通用医疗公司 |
与循环肿瘤细胞簇有关的方法以及癌症的治疗
|
WO2015061683A1
(en)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
|
WO2015065876A1
(en)
|
2013-10-29 |
2015-05-07 |
Thomas Jefferson University |
Methods of prevention or treatment for pathologic thrombosis or inflammation
|
EP3063165A1
(en)
|
2013-11-01 |
2016-09-07 |
Idenix Pharmaceuticals LLC |
D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
|
GB201319792D0
(en)
|
2013-11-08 |
2013-12-25 |
Sigmoid Pharma Ltd |
Formulations
|
CR20160254A
(es)
|
2013-11-11 |
2016-08-31 |
Naturex-Dbs Llc |
Composiciones y métodos útiles en el tratamiento de síntomas del tracto urinario inferior, hiperplasia prostática benigna, disfunción eréctil.
|
EP3074039A4
(en)
|
2013-11-26 |
2017-10-11 |
The Brigham and Women's Hospital, Inc. |
Compositions and methods for modulating an immune response
|
EP3074399A1
(en)
|
2013-11-27 |
2016-10-05 |
Idenix Pharmaceuticals LLC |
2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
|
US10030044B2
(en)
|
2013-11-27 |
2018-07-24 |
Idenix Pharmaceuticals Llc |
Nucleotides for the treatment of liver cancer
|
ES2912283T3
(es)
|
2013-12-11 |
2022-05-25 |
Massachusetts Gen Hospital |
Uso de proteínas de tipo sustancia inhibidora mülleriana (SIM) para la anticoncepción y conservación de la reserva ovárica
|
WO2015095419A1
(en)
|
2013-12-18 |
2015-06-25 |
Idenix Pharmaceuticals, Inc. |
4'-or nucleosides for the treatment of hcv
|
EP3082840B1
(en)
|
2013-12-20 |
2021-03-24 |
The General Hospital Corporation |
Methods and assays relating to circulating tumor cells
|
US9682123B2
(en)
|
2013-12-20 |
2017-06-20 |
The Trustees Of Columbia University In The City Of New York |
Methods of treating metabolic disease
|
EP3087073B1
(en)
|
2013-12-26 |
2018-07-04 |
Purdue Pharma LP |
10-substituted morphinan hydantoins
|
EP3087078B1
(en)
|
2013-12-26 |
2019-05-15 |
Purdue Pharma LP |
7-beta-alkyl analogs of orvinols
|
WO2015097545A1
(en)
|
2013-12-26 |
2015-07-02 |
Purdue Pharma L.P. |
Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
|
WO2015097546A1
(en)
|
2013-12-26 |
2015-07-02 |
Purdue Pharma L.P. |
Propellane-based compounds and their use as opioid receptor modulators
|
WO2015099863A1
(en)
|
2013-12-27 |
2015-07-02 |
Purdue Pharma L.P. |
6-substituted and 7-substituted morphinan analogs and the use thereof
|
EP3089978B1
(en)
|
2013-12-30 |
2018-08-29 |
Purdue Pharma L.P. |
Pyridone-sulfone morphinan analogs as opioid receptor ligands
|
ES2831326T3
(es)
|
2014-01-15 |
2021-06-08 |
Poxel Sa |
Métodos para tratar trastornos neurológicos, metabólicos y otros mediante el uso de pioglitazona enantiopura enriquecida con deuterio
|
WO2015112568A1
(en)
|
2014-01-24 |
2015-07-30 |
Celgene Corporation |
Methods for the treatment of obesity using apremilast
|
EP3114122A1
(en)
|
2014-03-05 |
2017-01-11 |
Idenix Pharmaceuticals LLC |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
US10080752B2
(en)
|
2014-03-10 |
2018-09-25 |
Kadmon Corporation, Llc |
Treatment of brain and central nervous system tumors
|
CN106458878B
(zh)
|
2014-03-18 |
2018-08-31 |
艾格埃克斯制药有限公司 |
2-氰基-3-环丙基-3-羟基-n-芳基-硫代丙烯酰胺衍生物
|
EP4066834A1
(en)
|
2014-03-19 |
2022-10-05 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
|
US11369588B2
(en)
|
2014-03-20 |
2022-06-28 |
The Trustees Of Princeton University |
NADPH production by the 10-formyl-THF pathway, and its use in the diagnosis and treatment of disease
|
AU2015231202B9
(en)
|
2014-03-20 |
2019-10-24 |
Capella Therapeutics, Inc. |
Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
|
CN106661027B
(zh)
|
2014-03-20 |
2019-12-24 |
卡佩拉医疗公司 |
苯并咪唑衍生物作为erbb酪氨酸激酶抑制剂用于治疗癌症
|
EP3119913B1
(en)
|
2014-03-21 |
2021-01-06 |
The Brigham and Women's Hospital, Inc. |
Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
|
US10426753B2
(en)
|
2014-04-03 |
2019-10-01 |
Invictus Oncology Pvt. Ltd. |
Supramolecular combinatorial therapeutics
|
EP3125905A4
(en)
|
2014-04-04 |
2017-11-08 |
Ritter Pharmaceuticals, Inc. |
Methods and compositions for microbiome alteration
|
WO2015157559A2
(en)
|
2014-04-09 |
2015-10-15 |
Siteone Therapeutics, Inc. |
10',11'-modified saxitoxins for the treatment of pain
|
WO2015161137A1
(en)
|
2014-04-16 |
2015-10-22 |
Idenix Pharmaceuticals, Inc. |
3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
|
AU2015249666A1
(en)
|
2014-04-25 |
2016-11-17 |
The Brigham And Women's Hospital, Inc. |
Compositions and methods for treating subjects with immune-mediated diseases
|
US20170044257A1
(en)
|
2014-04-25 |
2017-02-16 |
The Brigham And Women's Hospital, Inc. |
Methods to manipulate alpha-fetoprotein (afp)
|
WO2015168079A1
(en)
|
2014-04-29 |
2015-11-05 |
Infinity Pharmaceuticals, Inc. |
Pyrimidine or pyridine derivatives useful as pi3k inhibitors
|
WO2015175381A1
(en)
|
2014-05-12 |
2015-11-19 |
Conatus Pharmaceuticals, Inc. |
Treatment of the complications of chronic liver disease with caspase inhibitors
|
EP3142748B1
(en)
|
2014-05-15 |
2019-09-11 |
Celgene Corporation |
Use of pde4 inhibitors and combinations thereof for the treatment of cystic fibrosis
|
EP3142663A1
(en)
|
2014-05-16 |
2017-03-22 |
Celgene Corporation |
Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
|
CN106573872B
(zh)
|
2014-05-19 |
2021-07-20 |
东北大学 |
5-羟色胺受体靶向化合物和方法
|
EP3145500A1
(en)
|
2014-05-23 |
2017-03-29 |
Sigmoid Pharma Limited |
Celecoxib formulations useful for treating colorectal cancer
|
WO2015181624A2
(en)
|
2014-05-28 |
2015-12-03 |
Idenix Pharmaceuticals, Inc |
Nucleoside derivatives for the treatment of cancer
|
EP3148564B1
(en)
|
2014-06-02 |
2020-01-08 |
Children's Medical Center Corporation |
Methods and compositions for immunomodulation
|
JP2017519000A
(ja)
|
2014-06-12 |
2017-07-13 |
リガンド・ファーマシューティカルズ・インコーポレイテッド |
グルカゴンアンタゴニスト
|
US20150359810A1
(en)
|
2014-06-17 |
2015-12-17 |
Celgene Corporation |
Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
|
US9527815B2
(en)
|
2014-06-18 |
2016-12-27 |
Biotheryx, Inc. |
Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
|
BR112016029662B1
(pt)
|
2014-06-19 |
2023-10-24 |
Takeda Pharmaceutical Company Limited |
COMPOSTO DE FÓRMULA Bf OU UMA FORMA FARMACEUTICAMENTE ACEITÁVEL DO MESMO, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO O MESMO E SEU USO
|
ES2749433T3
(es)
|
2014-06-23 |
2020-03-20 |
Celgene Corp |
Apremilast para el tratamiento de una enfermedad hepática o una anomalía de la función hepática
|
JP6640126B2
(ja)
|
2014-06-27 |
2020-02-05 |
セルジーン コーポレイション |
セレブロン及び他のe3ユビキチンリガーゼの立体構造の変化を誘導するための組成物及び方法
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
CN106794233B
(zh)
|
2014-08-01 |
2021-11-12 |
布里格姆及妇女医院股份有限公司 |
与肺动脉高压的治疗有关的组合物和方法
|
WO2016025686A1
(en)
|
2014-08-15 |
2016-02-18 |
Celgene Corporation |
Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition
|
RS64038B1
(sr)
|
2014-08-22 |
2023-04-28 |
Celgene Corp |
Postupci za lečenje multiplog mijeloma imunomodulatornim jedinjenjima u kombinaciji sa antitelima
|
PL3186281T3
(pl)
|
2014-08-28 |
2019-10-31 |
Halozyme Inc |
Terapia skojarzona enzymem rozkładającym hialuronian i inhibitorem punktu kontrolnego odpowiedzi immunologicznej
|
CN107106704A
(zh)
|
2014-08-29 |
2017-08-29 |
儿童医疗中心有限公司 |
用于治疗癌症的方法和组合物
|
EP3191100A4
(en)
|
2014-09-12 |
2018-05-30 |
Tobira Therapeutics, Inc. |
Cenicriviroc combination therapy for the treatment of fibrosis
|
EA036391B1
(ru)
|
2014-09-15 |
2020-11-05 |
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния |
Нуклеотидные аналоги
|
JP7095990B2
(ja)
|
2014-09-18 |
2022-07-05 |
シーダーズ-サイナイ メディカル センター |
線維症を治療するための組成物及び方法
|
CA2961822A1
(en)
|
2014-09-18 |
2016-03-24 |
Tonix Pharma Holdings Limited |
Eutectic formulations of cyclobenzaprine hydrochloride
|
WO2016054491A1
(en)
|
2014-10-03 |
2016-04-07 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
PL3207130T3
(pl)
|
2014-10-14 |
2020-02-28 |
Halozyme, Inc. |
Kompozycje deaminazy adenozyny 2 (ada2), jej warianty i sposoby ich zastosowania
|
WO2016109002A2
(en)
|
2014-10-16 |
2016-07-07 |
Cleveland Biolabs, Inc. |
Methods and compositions for the treatment of radiation-related disorders
|
MX2017005120A
(es)
|
2014-10-21 |
2018-02-12 |
Ariad Pharma Inc |
Formas cristalinas de 5-cloro-n4-[-2-(dimetilfosforil) fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il] pirimidin-2,4-diamina.
|
US20170354639A1
(en)
|
2014-10-24 |
2017-12-14 |
Biogen Ma Inc. |
Diterpenoid derivatives and methods of use thereof
|
CN107106644B
(zh)
|
2014-11-07 |
2022-04-15 |
卓越治疗有限公司 |
包含环孢菌素的组合物
|
TW201702218A
(zh)
|
2014-12-12 |
2017-01-16 |
美國杰克森實驗室 |
關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
|
BR112017012646A2
(pt)
|
2014-12-16 |
2018-01-02 |
Celgene Corporation |
Formas sólidas compreendendo (1e, 4e)-2-amino- n,n-dipropil-8-(4-(pirrolidina-1-carbonil) fenil)-3h- benzo[b]azepina-4-carboxamida, composições das mesmas, e uso das mesmas
|
US9676793B2
(en)
|
2014-12-23 |
2017-06-13 |
Hoffmann-Laroche Inc. |
Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
|
US9546163B2
(en)
|
2014-12-23 |
2017-01-17 |
Axikin Pharmaceuticals, Inc. |
3,5-diaminopyrazole kinase inhibitors
|
CN107530423B
(zh)
|
2015-01-14 |
2022-04-05 |
布里格姆及妇女医院股份有限公司 |
用抗lap单克隆抗体治疗癌症
|
MX2017009406A
(es)
|
2015-01-20 |
2018-01-18 |
Xoc Pharmaceuticals Inc |
Compuestos de tipo isoergolina y usos de estos.
|
BR112017015487A2
(pt)
|
2015-01-20 |
2018-01-30 |
Xoc Pharmaceuticals Inc |
Composto; composição; método de tratamento e/ou prevenção de enxaqueca, als, doença de alzheimer, doença de parkinson, distúrbios extrapirimidais, depressão, náusea, êmese, síndrome das pernas inquietas, insônia, agressão, doença de huntington, doença cardiopulmonar, fibrogênese, hipertensão arterial pulmonar, ansiedade, dependências a drogas, distonia, parassonia ou hiperlactinemia em um indivíduo; métodos de agonização dos receptores d2, 5-ht1d, 5-ht1a e 5-ht2c, em um indivíduo; método de antagonização do receptor d3 em um indivíduo; métodos de agonização seletiva dos receptores 5 -ht1d, e 5-ht2c, método de fornecimento de atividade de antagonista funcional no receptor 5 -ht2b ou no receptor 5-ht7, ou em ambos, em um indivíduo; método de fornecimento de atividade de antagonista funcional nos receptores adrenérgicos em um indivíduo
|
EP3256161A1
(en)
|
2015-02-09 |
2017-12-20 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitors and pd-1 inhibitors for treating cancer
|
US10406152B2
(en)
|
2015-03-10 |
2019-09-10 |
Rhodes Technologies |
Acetate salt of buprenorphine and methods for preparing buprenorphine
|
TW201642857A
(zh)
|
2015-04-06 |
2016-12-16 |
西建公司 |
以組合療法治療肝細胞癌
|
US20180110823A1
(en)
|
2015-04-22 |
2018-04-26 |
Cedars-Sinai Medical Center |
Enterically delivered bitter oligopeptides for the treatment for type 2 diabetes
|
US10253024B2
(en)
|
2015-04-30 |
2019-04-09 |
The Regents Of The University Of Colorado, A Body Corporate |
Polycyclic indoline and indolenine compounds
|
CN108368147A
(zh)
|
2015-05-27 |
2018-08-03 |
南方研究院 |
用于治疗癌症的核苷酸
|
EP3303286B1
(en)
|
2015-06-01 |
2023-10-04 |
Cedars-Sinai Medical Center |
Compounds that bind to rela of nf-kb for use in treating cancer
|
WO2016202721A1
(en)
|
2015-06-16 |
2016-12-22 |
F. Hoffmann-La Roche Ag |
Salts of (s)-4-[(r)-6-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-3,6- dihydro-pyrimidin-4-ylmethyl]-morpholine-3-carboxylic acid, salt former and methods for preparing and using the same
|
CN113713108A
(zh)
|
2015-06-23 |
2021-11-30 |
纽罗克里生物科学有限公司 |
用于治疗神经学疾病或病症的vmat2抑制剂
|
EP3313818B1
(en)
|
2015-06-26 |
2023-11-08 |
Celgene Corporation |
Methods for the treatment of kaposi's sarcoma or kshv-induced lymphoma using immunomodulatory compounds, and uses of biomarkers
|
US10973822B2
(en)
|
2015-07-02 |
2021-04-13 |
Celgene Corporation |
Combination therapy for treatment of hematological cancers and solid tumors
|
WO2017017631A2
(en)
|
2015-07-28 |
2017-02-02 |
Vyome Biosciences Pvt. Ltd. |
Antibacterial therapeutics and prophylactics
|
WO2017023912A1
(en)
|
2015-08-03 |
2017-02-09 |
Temple University - Of The Commonwealth System Of Higher Education |
2,4,6-trialkoxystryl aryl sulfones, sulfonamides and carboxamides, and methods of preparation and use
|
PT3277842T
(pt)
|
2015-08-17 |
2019-09-05 |
Kura Oncology Inc |
Métodos de tratamento de doentes com cancro usando inibidores da farnesiltransferase
|
CN108602861A
(zh)
|
2015-08-27 |
2018-09-28 |
哈佛大学校长及研究员协会 |
用于治疗疼痛的组合物和方法
|
AU2016321298A1
(en)
|
2015-09-09 |
2018-03-29 |
The Trustees Of Columbia University In The City Of New York |
Reduction of ER-MAM localized APP-C99 and methods of treating Alzheimer's Disease
|
WO2017058828A1
(en)
|
2015-09-28 |
2017-04-06 |
Children's Hospital Los Angeles |
Methods for treating diseases mediated by erbb4-positive pro-inflammatory macrophages
|
JP2018534270A
(ja)
|
2015-09-30 |
2018-11-22 |
サイトワン セラピューティクス, インコーポレイテッド |
疼痛の治療のための11,13−修飾サキシトキシン
|
MX2018004022A
(es)
|
2015-10-01 |
2018-09-11 |
Heat Biologics Inc |
Composiciones y metodos para unir dominios extracelulares de tipo i y tipo ii como proteinas quimericas heterologas.
|
US20190255107A1
(en)
|
2015-10-09 |
2019-08-22 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
WO2017064657A1
(en)
|
2015-10-16 |
2017-04-20 |
Invictus Oncology Pvt. Ltd. |
Fluorescent anticancer platinum drugs
|
US10065952B2
(en)
|
2015-10-30 |
2018-09-04 |
Neurocrine Biosciences, Inc. |
Valbenazine salts and polymorphs thereof
|
WO2017079566A1
(en)
|
2015-11-05 |
2017-05-11 |
Conatus Pharmaceuticals, Inc. |
Caspase inhibitors for use in the treatment of liver cancer
|
EP3371311B1
(en)
|
2015-11-06 |
2021-07-21 |
Orionis Biosciences BV |
Bi-functional chimeric proteins and uses thereof
|
EP3373916A1
(en)
|
2015-11-11 |
2018-09-19 |
Celgene Corporation |
Controlled release oral dosage forms of poorly soluble drugs and uses thereof
|
US10112924B2
(en)
|
2015-12-02 |
2018-10-30 |
Astraea Therapeutics, Inc. |
Piperdinyl nociceptin receptor compounds
|
JP6869988B2
(ja)
|
2015-12-23 |
2021-05-12 |
ニューロクライン バイオサイエンシーズ,インコーポレイテッド |
(S)−(2R,3R,11bR)−3−イソブチル−9,10−ジメトキシ−2,3,4,6,7,11b−ヘキサヒドロ−1H−ピリド[2,1−a]イソキノリン−2−イル2−アミノ−3−メチルブタノエートジ(4−メチルベンゼンスルホネート)の調製のための合成方法
|
WO2017117118A1
(en)
|
2015-12-28 |
2017-07-06 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
|
KR20180101418A
(ko)
|
2015-12-31 |
2018-09-12 |
코나터스 파마슈티칼스, 인크. |
간 질환의 치료에서의 카스파제 억제제의 사용 방법
|
US10189808B2
(en)
|
2016-01-08 |
2019-01-29 |
Celgene Corporation |
Solid forms of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
|
BR112018013761A2
(pt)
|
2016-01-08 |
2018-12-11 |
Celgene Corp |
compostos antiproliferativos e suas composições farmacêuticas e usos
|
MX2018008421A
(es)
|
2016-01-08 |
2019-12-09 |
Celgene Corp |
Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
|
EP3998281A1
(en)
|
2016-02-05 |
2022-05-18 |
Orionis Biosciences BV |
Cd8 binding agents
|
US10179109B2
(en)
|
2016-03-04 |
2019-01-15 |
Charleston Laboratories, Inc. |
Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
|
EP3426278B1
(en)
|
2016-03-07 |
2024-01-03 |
Vib Vzw |
Cd20 binding single domain antibodies
|
US10759806B2
(en)
|
2016-03-17 |
2020-09-01 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
|
AU2017250086A1
(en)
|
2016-04-11 |
2018-09-20 |
Clexio Biosciences Ltd. |
Deuterated ketamine derivatives
|
US10047077B2
(en)
|
2016-04-13 |
2018-08-14 |
Skyline Antiinfectives, Inc. |
Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
|
US20190119758A1
(en)
|
2016-04-22 |
2019-04-25 |
Kura Oncology, Inc. |
Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
|
CN109476635B
(zh)
|
2016-04-29 |
2021-07-13 |
Fgh生物科技公司 |
用于治疗疾病的二取代吡唑类化合物
|
US10858326B2
(en)
|
2016-05-04 |
2020-12-08 |
Purdue Pharma L.P. |
Oxazoline pseudodimers, pharmaceutical compositions and the use thereof
|
JP7105200B2
(ja)
|
2016-05-13 |
2022-07-22 |
オリオニス バイオサイエンシズ ビーブイ |
標的突然変異体インターフェロン-ベータおよびその使用
|
WO2017194782A2
(en)
|
2016-05-13 |
2017-11-16 |
Orionis Biosciences Nv |
Therapeutic targeting of non-cellular structures
|
TWI753910B
(zh)
|
2016-05-16 |
2022-02-01 |
美商拜歐斯瑞克斯公司 |
吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
|
US10919914B2
(en)
|
2016-06-08 |
2021-02-16 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
AU2017298648B2
(en)
|
2016-07-18 |
2023-05-11 |
Pharmena S.A. |
1-methylnicotinamide for the treatment of diseases associated with C-reactive protein
|
JOP20190008A1
(ar)
|
2016-07-26 |
2019-01-24 |
Purdue Pharma Lp |
علاج ومنع اضطرابات النوم
|
CN116514761A
(zh)
|
2016-07-29 |
2023-08-01 |
赛诺维信制药公司 |
化合物、组合物及其用途
|
EP3490607A4
(en)
|
2016-07-29 |
2020-04-08 |
Sunovion Pharmaceuticals Inc. |
COMPOUNDS AND COMPOSITIONS, AND USES THEREOF
|
EP3510027B1
(en)
|
2016-09-07 |
2022-11-02 |
FGH BioTech, Inc. |
Di-substituted pyrazole compounds for the treatment of diseases
|
US10729670B2
(en)
|
2016-09-07 |
2020-08-04 |
Temple University—Of The Commonwealth Systems Of Higher Education |
Compositions and methods for treatment of insulin resistance
|
FR3055800B1
(fr)
*
|
2016-09-15 |
2020-06-26 |
Unither Pharmaceuticals |
Composition solide a ingestion rapide et deglutition facilitee, sous forme de particules solides non agglomerees, comprenant deux differents types de particules
|
US20190201409A1
(en)
|
2016-09-19 |
2019-07-04 |
Mei Pharma, Inc. |
Combination therapy
|
US20200016202A1
(en)
|
2016-10-07 |
2020-01-16 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
EP4112053B1
(en)
|
2016-10-11 |
2024-02-14 |
Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) |
Treatment of synucleinopathies
|
US11154591B2
(en)
|
2016-10-14 |
2021-10-26 |
The Trustees Of Columbia University In The City Of New York |
Methods of treating alcohol abuse disorder
|
CN110072522A
(zh)
|
2016-10-21 |
2019-07-30 |
美国大仁医疗有限公司 |
提高癌细胞对顺铂的敏感性的物质和方法
|
ES2917000T3
(es)
|
2016-10-24 |
2022-07-06 |
Orionis Biosciences BV |
Interferón-gamma mutante diana y usos del mismo
|
EP3838275A1
(en)
|
2016-11-03 |
2021-06-23 |
Kura Oncology, Inc. |
Farnesyltransferase inhibitors for use in methods of treating cancer
|
US10106521B2
(en)
|
2016-11-09 |
2018-10-23 |
Phloronol, Inc. |
Eckol derivatives, methods of synthesis and uses thereof
|
CN116987014A
(zh)
|
2016-11-09 |
2023-11-03 |
诺沃梅迪科斯有限公司 |
1,1-二甲双胍的亚硝酸盐、药物组合物和使用方法
|
CN110191705A
(zh)
|
2016-12-01 |
2019-08-30 |
亚尼塔公司 |
治疗癌症的方法
|
TW201827051A
(zh)
|
2016-12-02 |
2018-08-01 |
美商神經性分泌生物科學公司 |
戊苯那嗪(valbenazine)於治療精神分裂症或情感性精神分裂症之用途
|
CA3051829A1
(en)
|
2017-01-27 |
2018-08-02 |
Neurocrine Bioscienes, Inc. |
Methods for the administration of certain vmat2 inhibitors
|
EP3573979A1
(en)
|
2017-01-27 |
2019-12-04 |
Celgene Corporation |
3-(1-oxo-4-((4-((3-oxomorpholino) methyl)benzyl)oxy)isoindolin-2-yl)piperidine-2,6-dione and isotopologues thereof
|
KR102642385B1
(ko)
|
2017-02-06 |
2024-03-04 |
오리오니스 바이오사이언시스 엔브이 |
표적화된 키메라 단백질 및 이의 용도
|
MX2019009288A
(es)
|
2017-02-06 |
2019-09-10 |
Spero Therapeutics Inc |
Formas cristalinas de tebipenem pivoxil, composiciones que incluyen a las mismas, metodos de fabricacion, y metodos de utilizacion.
|
US10906985B2
(en)
|
2017-02-06 |
2021-02-02 |
Orionis Biosciences, Inc. |
Targeted engineered interferon and uses thereof
|
US11246911B2
(en)
|
2017-02-07 |
2022-02-15 |
Vib Vzw |
Immune-cell targeted bispecific chimeric proteins and uses thereof
|
CA3053903A1
(en)
|
2017-02-16 |
2018-08-23 |
Sunovion Pharmaceuticals Inc. |
Methods of treating schizophrenia
|
TWI693074B
(zh)
|
2017-02-21 |
2020-05-11 |
美商庫拉腫瘤技術股份有限公司 |
以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症之方法
|
US9956215B1
(en)
|
2017-02-21 |
2018-05-01 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
AU2018224852A1
(en)
|
2017-02-27 |
2019-07-11 |
Shattuck Labs, Inc. |
VSIG8-based chimeric proteins
|
WO2018164996A1
(en)
|
2017-03-06 |
2018-09-13 |
Neurocrine Biosciences, Inc. |
Dosing regimen for valbenazine
|
WO2018165142A1
(en)
|
2017-03-07 |
2018-09-13 |
Celgene Corporation |
Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
|
WO2018175324A1
(en)
|
2017-03-20 |
2018-09-27 |
The Broad Institute, Inc. |
Compounds and methods for regulating insulin secretion
|
US11167003B2
(en)
|
2017-03-26 |
2021-11-09 |
Mapi Pharma Ltd. |
Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems
|
US11279706B2
(en)
|
2017-03-29 |
2022-03-22 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
AU2018243463C1
(en)
|
2017-03-29 |
2022-12-01 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
WO2018200605A1
(en)
|
2017-04-26 |
2018-11-01 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating levodopa-induced dyskinesia
|
JOP20190219A1
(ar)
|
2017-05-09 |
2019-09-22 |
Cardix Therapeutics LLC |
تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
|
US10085999B1
(en)
|
2017-05-10 |
2018-10-02 |
Arixa Pharmaceuticals, Inc. |
Beta-lactamase inhibitors and uses thereof
|
KR102642411B1
(ko)
|
2017-05-19 |
2024-02-28 |
엔플렉션 테라퓨틱스, 인코포레이티드 |
피부병 치료를 위한 피롤로피리딘-아닐린 화합물
|
US10988483B2
(en)
|
2017-05-19 |
2021-04-27 |
Nflection Therapeutics, Inc. |
Fused heteroaromatic-aniline compounds for treatment of dermal disorders
|
WO2018222831A1
(en)
|
2017-05-31 |
2018-12-06 |
The Children's Medical Center Corporation |
TARGETING LYSINE DEMETHYLASES (KDMs) AS A THERAPEUTIC STRATEGY FOR DIFFUSE LARGE B-CELL LYMPHOMA
|
BR112019025420A2
(pt)
|
2017-06-01 |
2020-06-16 |
Xoc Pharmaceuticals, Inc. |
Compostos policíclicos e usos destes
|
WO2019005874A1
(en)
|
2017-06-26 |
2019-01-03 |
The Trustees Of Columbia University In The City Of New York |
CHOLINERGIC AGONISM FOR THE TREATMENT OF PANCREATIC CANCER
|
JP7097438B2
(ja)
|
2017-07-11 |
2022-07-07 |
アクティム・セラピューティクス・インコーポレイテッド |
遺伝子操作された免疫刺激性細菌菌株およびその使用
|
JP2020526592A
(ja)
|
2017-07-13 |
2020-08-31 |
トニックス ファーマシューティカルズ ホールディング コーポレーション |
シクロベンザプリン類似体及びアミトリプチレン類似体
|
WO2019018247A1
(en)
|
2017-07-16 |
2019-01-24 |
Neuere, Llc |
USE OF AMBROXOL TO IMPROVE AND / OR EXTEND THE LIFETIME IN GOOD HEALTH, LIFETIME AND / OR MENTAL ACUITY
|
SG11202000669VA
(en)
|
2017-08-02 |
2020-02-27 |
Sunovion Pharmaceuticals Inc |
Isochroman compounds and uses thereof
|
US10806730B2
(en)
|
2017-08-07 |
2020-10-20 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
CN111182899A
(zh)
|
2017-08-07 |
2020-05-19 |
库拉肿瘤学公司 |
使用法尼基转移酶抑制剂治疗癌症的方法
|
JP7250006B2
(ja)
|
2017-09-21 |
2023-03-31 |
ニューロクライン バイオサイエンシーズ,インコーポレイテッド |
高投与量バルベナジン製剤ならびにそれに関連する組成物、方法およびキット
|
AU2018345321B2
(en)
|
2017-10-02 |
2021-05-20 |
Arixa Pharmaceuticals, Inc. |
Aztreonam derivatives and uses thereof
|
KR20200066661A
(ko)
|
2017-10-10 |
2020-06-10 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
US10993941B2
(en)
|
2017-10-10 |
2021-05-04 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
WO2019097080A1
(en)
|
2017-11-20 |
2019-05-23 |
Kiakos Konstantinos |
3,5-diarylidenyl-n-substituted-piperid-4-one-derived inhibitors of stat3 pathway acitivty and uses therof
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
CA3083341A1
(en)
|
2017-12-11 |
2019-06-20 |
Tonix Pharma Holdings Limited |
Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
|
EP3723775A4
(en)
|
2017-12-15 |
2022-04-13 |
Solarea Bio, Inc. |
MICROBIAL COMPOSITIONS AND METHODS OF TREATMENT OF TYPE 2 DIABETES, OBESITY AND METABOLIC SYNDROME
|
US11708335B2
(en)
|
2017-12-18 |
2023-07-25 |
Sterngreene, Inc. |
Pyrimidine compounds useful as tyrosine kinase inhibitors
|
WO2019136314A1
(en)
|
2018-01-05 |
2019-07-11 |
The Curators Of The University Of Missouri |
Compounds and methods for treatment of cystic fibrosis
|
EP3737382A1
(en)
|
2018-01-10 |
2020-11-18 |
Cura Therapeutics, LLC |
Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
|
WO2019139871A1
(en)
|
2018-01-10 |
2019-07-18 |
Cura Therapeutics Llc |
Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
|
MX2020007817A
(es)
|
2018-01-24 |
2020-09-25 |
Purdue Pharma Lp |
Prevención y tratamiento del trastorno del sueño.
|
US11896643B2
(en)
|
2018-02-05 |
2024-02-13 |
Orionis Biosciences, Inc. |
Fibroblast binding agents and use thereof
|
AU2019217207A1
(en)
|
2018-02-12 |
2020-08-27 |
Diabetes-Free, Inc. |
Improved antagonistic anti-human CD40 monoclonal antibodies
|
WO2019161236A1
(en)
|
2018-02-16 |
2019-08-22 |
Sunovion Pharmaceuticals Inc. |
Methods of treating social function disorders
|
CA3090807A1
(en)
|
2018-02-21 |
2019-08-29 |
AI Therapeutics, Inc. |
Combination therapy with apilimod and glutamatergic agents
|
WO2019182683A1
(en)
|
2018-03-22 |
2019-09-26 |
The Children's Medical Center Corporation |
Methods and compositions relating to lung repair
|
WO2019222435A1
(en)
|
2018-05-16 |
2019-11-21 |
Halozyme, Inc. |
Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
|
EP3806856A1
(en)
|
2018-06-14 |
2021-04-21 |
Neurocrine Biosciences, Inc. |
Vmat2 inhibitor compounds, compositions, and methods relating thereto
|
EP3814327A1
(en)
|
2018-06-29 |
2021-05-05 |
Histogen, Inc. |
(s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
|
BR112021000315A2
(pt)
|
2018-07-11 |
2021-08-03 |
Actym Therapeutics, Inc. |
cepas bacterianas imunoestimulantes modificadas geneticamente e seus usos
|
BR112021000019A2
(pt)
|
2018-08-15 |
2021-04-06 |
Neurocrine Biosciences Inc. |
Métodos para administração de certos inibidores de vmat2
|
EP3844276A2
(en)
|
2018-08-28 |
2021-07-07 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
JP2022511286A
(ja)
|
2018-08-29 |
2022-01-31 |
シャタック ラボ,インコーポレイテッド |
Sirpアルファ系キメラタンパク質を含む併用療法
|
CA3111795A1
(en)
|
2018-09-05 |
2020-03-12 |
Solarea Bio, Inc. |
Methods and compositions for treating musculoskeletal diseases
|
US11180500B2
(en)
|
2018-10-01 |
2021-11-23 |
Arixa Pharmaceuticals, Inc. |
Derivatives of relebactam and uses thereof
|
US20220009938A1
(en)
|
2018-10-03 |
2022-01-13 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
WO2020092720A2
(en)
|
2018-11-01 |
2020-05-07 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
WO2020102454A1
(en)
|
2018-11-13 |
2020-05-22 |
Regents Of The University Of Minnesota |
Cd40 targeted peptides and uses thereof
|
CA3120337A1
(en)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Naphthyridinone-aniline compounds for treatment of dermal disorders
|
AU2019383311A1
(en)
|
2018-11-20 |
2021-06-10 |
Nflection Therapeutics, Inc. |
Cyanoaryl-aniline compounds for treatment of dermal disorders
|
WO2020106307A1
(en)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Aryl-aniline and heteroaryl-aniline compounds for treatment of birthmarks
|
MA55143A
(fr)
|
2018-11-20 |
2021-09-29 |
H Lee Moffitt Cancer Center & Res Institute Inc |
Composés aryl-aniline et hétéroaryl-aniline pour le traitement de cancers de la peau
|
US20230078755A1
(en)
|
2018-12-19 |
2023-03-16 |
Shy Therapeutics, Llc |
Compounds that Interact with the RAS Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease
|
WO2020132700A1
(en)
|
2018-12-21 |
2020-06-25 |
Fgh Biotech Inc. |
Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
|
AU2019403379A1
(en)
|
2018-12-21 |
2021-07-15 |
Kura Oncology, Inc. |
Therapies for squamous cell carcinomas
|
EP3921038A1
(en)
|
2019-02-06 |
2021-12-15 |
Dice Alpha, Inc. |
Il-17a modulators and uses thereof
|
CA3131017A1
(en)
|
2019-02-27 |
2020-09-03 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
|
US20220142983A1
(en)
|
2019-03-01 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
TW202100506A
(zh)
|
2019-03-07 |
2021-01-01 |
美商柯納特斯製藥公司 |
半胱天冬酶(caspase)抑制劑及其使用方法
|
JP2022524118A
(ja)
|
2019-03-12 |
2022-04-27 |
アリクサ ファーマシューティカルズ、インコーポレイテッド |
アビバクタム誘導体の結晶形
|
KR20210139376A
(ko)
|
2019-03-14 |
2021-11-22 |
선오비온 파마슈티컬스 인코포레이티드 |
이소크로마닐 화합물의 염, 및 이의 결정성 형태, 제조방법, 치료 용도 및 약제학적 조성물
|
TW202108170A
(zh)
|
2019-03-15 |
2021-03-01 |
美商庫拉腫瘤技術股份有限公司 |
以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症患者之方法
|
WO2020193431A1
(en)
|
2019-03-22 |
2020-10-01 |
Deutsches Krebsforschungszentrum |
Novel inhibitors of histone deacetylase 10
|
EP3712127A1
(en)
|
2019-03-22 |
2020-09-23 |
Deutsches Krebsforschungszentrum |
Novel inhibitors of histone deacetylase 10
|
CA3134825A1
(en)
|
2019-03-29 |
2020-10-08 |
Kura Oncology, Inc. |
Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
|
WO2020205387A1
(en)
|
2019-04-01 |
2020-10-08 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
JP2022527825A
(ja)
|
2019-04-03 |
2022-06-06 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
薬物送達のためのイオン液体
|
US11565999B2
(en)
|
2019-04-25 |
2023-01-31 |
Arixa Pharmaceuticals, Inc. |
Methods of synthesizing aztreonam derivatives
|
WO2020223583A1
(en)
|
2019-05-02 |
2020-11-05 |
Kura Oncology, Inc. |
Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
|
WO2020227437A1
(en)
|
2019-05-06 |
2020-11-12 |
Axial Biotherapeutics, Inc. |
Sustained release solid dosage forms for modulating the colonic microbiome
|
CN113874375A
(zh)
|
2019-06-03 |
2021-12-31 |
株式会社大分大学先端医学研究所 |
用于治疗狂犬病的环状酰胺化合物及其方法
|
CA3143713A1
(en)
|
2019-06-19 |
2020-12-24 |
Solarea Bio, Inc. |
Microbial compositions and methods for producing upgraded probiotic assemblages
|
US20220274921A1
(en)
|
2019-07-11 |
2022-09-01 |
Cura Therapeutics, Llc |
Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
|
EP3997068A1
(en)
|
2019-07-11 |
2022-05-18 |
Cura Therapeutics, LLC |
Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
|
CA3143294A1
(en)
|
2019-07-26 |
2021-02-04 |
Espervita Therapeutics, Inc. |
Functionalized long-chain hydrocarbon mono- and di-carboxylic acids useful for the prevention or treatment of disease
|
US11654124B2
(en)
|
2019-07-29 |
2023-05-23 |
Amneal Pharmaceuticals Llc |
Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
|
US10792262B1
(en)
|
2019-07-29 |
2020-10-06 |
Saol International Limited |
Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
CA3152665A1
(en)
|
2019-08-27 |
2021-03-04 |
Tonix Pharma Limited |
Modified tff2 polypeptides
|
AU2020348685A1
(en)
|
2019-09-16 |
2022-04-14 |
Dice Alpha, Inc. |
IL-17A modulators and uses thereof
|
US20230008367A1
(en)
|
2019-09-26 |
2023-01-12 |
Abionyx Pharma Sa |
Compounds useful for treating liver diseases
|
TW202126631A
(zh)
|
2019-10-01 |
2021-07-16 |
美商分子皮膚療法公司 |
作為klk5/7雙重抑制劑之苯并酮化合物
|
CA3161450A1
(en)
|
2019-11-12 |
2021-05-20 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products
|
US20240016735A1
(en)
|
2019-11-22 |
2024-01-18 |
President And Fellows Of Harvard College |
Ionic liquids for drug delivery
|
AU2020396866A1
(en)
|
2019-12-02 |
2022-06-23 |
Celgene Corporation |
Therapy for the treatment of cancer
|
WO2021183318A2
(en)
|
2020-03-09 |
2021-09-16 |
President And Fellows Of Harvard College |
Methods and compositions relating to improved combination therapies
|
CN113367378A
(zh)
*
|
2020-03-09 |
2021-09-10 |
深圳波顿香料有限公司 |
一种水爆珠的制备方法
|
TW202206062A
(zh)
|
2020-04-24 |
2022-02-16 |
美國坦普大學 高等教育聯邦系統 |
治療非酒精性脂肪肝炎的方法
|
US20230102247A1
(en)
|
2020-04-28 |
2023-03-30 |
President And Fellows Of Harvard College |
Methods and compositions relating to ionic liquid adjuvants
|
WO2021226033A1
(en)
|
2020-05-07 |
2021-11-11 |
President And Fellows Of Harvard College |
Hyaluronic acid drug conjugates
|
WO2021242794A2
(en)
|
2020-05-29 |
2021-12-02 |
President And Fellows Of Harvard College |
Living cells engineered with polyphenol-functionalized biologically active nanocomplexes
|
EP4157271A1
(en)
|
2020-05-29 |
2023-04-05 |
Boulder Bioscience LLC |
Methods for improved endovascular thrombectomy using 3,3'-diindolylmethane
|
US20230227466A1
(en)
|
2020-06-18 |
2023-07-20 |
Shy Therapeutics, Llc |
Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
WO2021262579A1
(en)
|
2020-06-23 |
2021-12-30 |
President And Fellows Of Harvard College |
Compositions and methods relating to combinatorial hyaluronic acid conjugates
|
US11319313B2
(en)
|
2020-06-30 |
2022-05-03 |
Poxel Sa |
Crystalline forms of deuterium-enriched pioglitazone
|
CN116600824A
(zh)
|
2020-07-10 |
2023-08-15 |
巴斯德研究所 |
Gdf11诊断和治疗焦虑症和抑郁症的用途
|
AU2021324883A1
(en)
|
2020-08-12 |
2023-03-23 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms
|
JP2023537632A
(ja)
|
2020-08-14 |
2023-09-04 |
サイトワン セラピューティクス インコーポレイテッド |
疼痛の処置のためのNaV1.7の非水和ケトン阻害剤
|
US11541009B2
(en)
|
2020-09-10 |
2023-01-03 |
Curemark, Llc |
Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
|
TW202233173A
(zh)
|
2020-10-30 |
2022-09-01 |
愛爾蘭商Ds生物製藥有限公司 |
包括15-HETrE之醫藥組合物及其使用方法
|
WO2022155410A1
(en)
|
2021-01-15 |
2022-07-21 |
President And Fellows Of Harvard College |
Methods and compositions relating to anti-mfsd2a antibodies
|
EP4284394A1
(en)
|
2021-01-26 |
2023-12-06 |
Cytocares (Shanghai) Inc. |
Chimeric antigen receptor (car) constructs and nk cells expressing car constructs
|
EP4284377A1
(en)
|
2021-01-27 |
2023-12-06 |
Shy Therapeutics LLC |
Methods for the treatment of fibrotic disease
|
WO2022165000A1
(en)
|
2021-01-27 |
2022-08-04 |
Shy Therapeutics, Llc |
Methods for the treatment of fibrotic disease
|
WO2022187573A1
(en)
|
2021-03-05 |
2022-09-09 |
President And Fellows Of Harvard College |
Methods and compositions relating to cell membrane hybridization and camouflaging
|
WO2022189010A1
(en)
|
2021-03-07 |
2022-09-15 |
Givaudan Sa |
Methods and compositions for treating and preventing urinary tract infections
|
WO2022189856A1
(en)
|
2021-03-08 |
2022-09-15 |
Abionyx Pharma Sa |
Compounds useful for treating liver diseases
|
BR112023018290A2
(pt)
|
2021-03-10 |
2023-12-12 |
Dice Molecules Sv Inc |
Inibidores da integrina alfa v beta 6 e alfa v beta 1 e usos dos mesmos
|
WO2022198002A1
(en)
|
2021-03-19 |
2022-09-22 |
Tiba Biotech Llc |
Artificial alphavirus-derived rna replicon expression systems
|
WO2022226166A1
(en)
|
2021-04-22 |
2022-10-27 |
Protego Biopharma, Inc. |
Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
|
EP4347568A1
(en)
|
2021-05-27 |
2024-04-10 |
Protego Biopharma, Inc. |
Heteroaryl diamide ire1/xbp1s activators
|
WO2022265880A1
(en)
|
2021-06-16 |
2022-12-22 |
President And Fellows Of Harvard College |
Improved methods and compositions for drug delivery relating to ionic liquids
|
WO2022271537A1
(en)
|
2021-06-25 |
2022-12-29 |
President And Fellows Of Harvard College |
Compositions and methods relating to injectable microemulsions
|
KR20240044458A
(ko)
|
2021-08-05 |
2024-04-04 |
브리스톨-마이어스 스큅 컴퍼니 |
Her2 억제제로서 사용하기 위한 트리시클릭 융합된 피리미딘 화합물
|
WO2023034508A1
(en)
|
2021-09-01 |
2023-03-09 |
Flagship Pioneering Innovations Vi, Llc |
Methods and compositions for promoting adipocyte beiging
|
WO2023034504A1
(en)
|
2021-09-01 |
2023-03-09 |
Flagship Pioneering Innovations Vi, Llc |
Methods and compositions for inducing fetal hemoglobin, modulating erythroid cell lineages, and perturbing megakaryocyte lineages
|
US20230144855A1
(en)
|
2021-09-01 |
2023-05-11 |
Flagship Pioneering Innovations Vi, Llc |
Methods and compositions for inducing fetal hemoglobin
|
WO2023034507A1
(en)
|
2021-09-01 |
2023-03-09 |
Flagship Pioneering Innovations Vi, Llc |
In vivo and ex vivo methods of modulating t cell exhaustion/de-exhaustion
|
WO2023039164A2
(en)
|
2021-09-09 |
2023-03-16 |
Flagship Pioneering Innovations Vi, Llc |
Methods and compositions for modulating goblet cells and for muco-obstructive diseases
|
US20230077584A1
(en)
|
2021-09-09 |
2023-03-16 |
Flagship Pioneering Innovations Vi, Llc |
Methods and compositions for modulating enteroendocrine cells
|
WO2023043827A2
(en)
|
2021-09-14 |
2023-03-23 |
Flagship Pioneering Innovations Vi, Llc |
Methods and compositions for perturbing monocyte and neutrophil lineages
|
WO2023055457A1
(en)
|
2021-09-29 |
2023-04-06 |
Amneal Pharmaceuticals Llc |
Baclofen-containing granule formulations and reduced patient exposure to metabolite variations
|
CA3233824A1
(en)
|
2021-10-08 |
2023-04-13 |
Samir Mitragotri |
Ionic liquids for drug delivery
|
EP4162933A1
(en)
|
2021-10-08 |
2023-04-12 |
Algiax Pharmaceuticals GmbH |
Compound for treating non-alcoholic fatty liver disease and related diseases
|
WO2023076997A1
(en)
|
2021-10-28 |
2023-05-04 |
Zywie, Llc |
Modified forms of ambroxol for therapeutic use
|
WO2023092150A1
(en)
|
2021-11-22 |
2023-05-25 |
Solarea Bio, Inc. |
Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
|
AU2022399572A1
(en)
|
2021-11-30 |
2024-05-02 |
Kura Oncology, Inc. |
Macrocyclic compounds having farnesyltransferase inhibitory activity
|
US20230190834A1
(en)
|
2021-12-21 |
2023-06-22 |
Solarea Bio, Inc. |
Immunomodulatory compositions comprising microbial entities
|
US11932665B2
(en)
|
2022-01-03 |
2024-03-19 |
Lilac Therapeutics, Inc. |
Cyclic thiol prodrugs
|
WO2023168426A1
(en)
|
2022-03-03 |
2023-09-07 |
Enosi Therapeutics Corporation |
Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof
|
US20230303580A1
(en)
|
2022-03-28 |
2023-09-28 |
Isosterix, Inc. |
Inhibitors of the myst family of lysine acetyl transferases
|
TW202342070A
(zh)
|
2022-03-30 |
2023-11-01 |
美商拜奧馬林製藥公司 |
肌萎縮蛋白外顯子跳躍寡核苷酸
|
GB2619907A
(en)
|
2022-04-01 |
2023-12-27 |
Kanna Health Ltd |
Novel crystalline salt forms of mesembrine
|
WO2023201282A1
(en)
|
2022-04-14 |
2023-10-19 |
Bristol-Myers Squibb Company |
Novel gspt1 compounds and methods of use of the novel compounds
|
WO2023201348A1
(en)
|
2022-04-15 |
2023-10-19 |
Celgene Corporation |
Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma
|
WO2023211990A1
(en)
|
2022-04-25 |
2023-11-02 |
Siteone Therapeutics, Inc. |
Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
|
US20230416741A1
(en)
|
2022-05-05 |
2023-12-28 |
Biomarin Pharmaceutical Inc. |
Method of treating duchenne muscular dystrophy
|
WO2023230524A1
(en)
|
2022-05-25 |
2023-11-30 |
Flagship Pioneering Innovations Vi, Llc |
Compositions of secretory and/or catalytic cells and methods using the same
|
WO2024054832A1
(en)
|
2022-09-09 |
2024-03-14 |
Innovo Therapeutics, Inc. |
CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS
|
WO2024073473A1
(en)
|
2022-09-30 |
2024-04-04 |
Boulder Bioscience Llc |
Compositions comprising 3,3'-diindolylmethane for treating non-hemorrhagic closed head injury
|
WO2024086246A2
(en)
|
2022-10-18 |
2024-04-25 |
Eluciderm Inc. |
2-substituted 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3- djpyrimidin-4-ones for wound treatment
|
WO2024091863A1
(en)
|
2022-10-25 |
2024-05-02 |
Starrock Pharma Llc |
Combinatorial, and rotational combinatorial therapies for obesity and other diseases
|
WO2024092043A1
(en)
|
2022-10-26 |
2024-05-02 |
Protego Biopharma, Inc. |
Spirocycle containing pyridine compounds
|
WO2024092037A1
(en)
|
2022-10-26 |
2024-05-02 |
Protego Biopharma, Inc. |
Spirocycle containing pyridone compounds
|
WO2024092040A1
(en)
|
2022-10-26 |
2024-05-02 |
Protego Biopharma, Inc. |
Spirocycle containing bicyclic heteroaryl compounds
|